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LIST OF ABBREVIATIONS 
RBPs: RNA-binding proteins 
RBDs: RNA-binding domains 
mRBPs: messenger RNA-binding proteins 
RRM: RNA recognition motif 
KH: K homology 
DSRM: double-stranded RNA-binding motif 
Puf: Pumilio 
snRNA: small nuclear RNA 
snoRNA: small nucleolar RNA 
ncRNA: non-coding RNA 
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UNR: upstream of N-Ras 
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STAR: signal transduction and activators of RNA 
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3’-UTR: 3’ untranslated region 
CPEB: cytoplasmic polyadenylation element binding 
TPA: tissue plasminogen activator 
VEGF: vascular endothelial growth factor 
ARE: AU-rich element 
AUBPs: ARE-binding proteins 
IRES: internal ribosome entry site 
EMT: epithelial to mesenchymal transition 
IMP1: insulin-like growth factor 2 mRNA binding protein 1 
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TRAP1: tumour necrosis factor receptor-associated protein 1 
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ER: endoplasmic reticulum 
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53BP1: P53-binding protein 1 
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MITO: mitochondrial 
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GE: Gene Expression 
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ABSTRACT 
RNA-binding proteins (RBPs) are key players in the post-
transcriptional regulation of gene expression, regulating each step of 
RNA metabolism, from synthesis to decay through a dynamic 
association. Accordingly, the repertoire of new non-canonical RBPs 
has consistently grown in the last few years. Given that post-
transcriptional events play pivotal roles in the adaption of cells to the 
local microenvironment, it is common that perturbations of RBP-
networks can lead to cancer through mechanisms that are still poorly 
understood. In this context, we investigated the role played by 
TRAP1, a molecular chaperone whose role in cancer has been 
extensively described, and its predicted interacting-partner Protein 
Syndesmos (SDOS). SDOS, also known as Nudt16l1, is a paralog of 
the catalytic nuclear Nudt16p family of proteins that has been 
predicted to lack the decapping activity. This work demonstrates that 
SDOS interacts with TRAP1, as shown by co-immunoprecipitation 
and proximity ligation assays. Moreover, SDOS associates with 
actively translating polyribosomes and takes part to stress granules, 
being involved in the downmodulation of mRNA translation. By both 
polynucleotide kinase (PNK) assay and small-scale RNA interactome 
capture, we demonstrated, for the first time, that SDOS and TRAP1 
are novel, non-canonical RBPs. Consequently, we have characterized 
the RNA-binding properties of SDOS and TRAP1, by combining 
three high-throughput approaches: i) individual nucleotide cross-
linking and immunoprecipitation (iCLIP) sequencing, to identify 
direct RNA targets; ii) Ribosome profiling sequencing, to identify 
differentially translated targets and iii) Gene expression analysis, to 
identify differentially expressed genes. Combination of these analyses 
allowed us to identify several crucial regulated pathways and, among 
those, we focused our attention on a small subset of genes responsible 
for ciliopathies, a class of rare diseases caused by defects in primary 
cilia. Among them we confirmed TMEM107, a ciliary transition zone 
protein, as directly bound at RNA level by SDOS, as demonstrated by 
RNA-immunoprecipitation analysis. Moreover, TMEM107 
translational regulation by SDOS was demonstrated by western blot 
and qPCR assays. Taken together these findings suggest that SDOS 
might regulate primary cilia formation. Intriguingly, a new area of 
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research is emerging linking cilia to cancer, suggesting the existence 
of a bridge between SDOS and TRAP1 functions and related diseases.
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1. INTRODUCTION 
1.1. RNA-binding proteins 
RNA-binding proteins (RBPs) represent about 7.5% of the eukaryotic 
proteome, belonging to a group of conserved, abundant, and 
ubiquitously expressed proteins, mostly involved in the post-
transcriptional regulation of gene expression1. These proteins bind 
specific regions of mRNAs, regulating each step of their life cycle, 
from synthesis to decay. RBPs recognise and bind short stretches of 
RNA due to the presence of specific amino acid motifs in their 
structure, therefore known as RNA-binding domains (RBDs)2 - even 
though recent studies demonstrated that this statement is not entirely 
true, with novel identified RBPs lacking the classical RBDs. Although 
the multiple roles played by RBPs would suggest a large diversity in 
the structures responsible for the RNA recognition, most RBPs are 
actually built from a small number of RNA-binding modules. Thus, 
the recognition of a large diversity of substrates is ensured by the 
combination of multiple copies of these RBDs, that function together 
as a single RNA recognition unit3. Recently, it has been published a 
census of 1542 human RBPs which contain a repertoire of ~600 
structurally distinct RBDs. Among the others, messenger RNA-
binding proteins (mRBPs), are the most abundant across the different 
RBDs-based classes of RBPs. About 405 of the 692 mRBPs identified 
contain an RNA recognition motif (RRM), a K homology (KH) 
domain, a DEAD motif, a double-stranded RNA-binding motif 
(DSRM) or a zinc-finger domain, which are among the most well-
known and characterized domains. Conversely, ribosomal proteins 
have 119 distinct domains, and they are exclusively found in this 
protein family1. Messenger RBD classes usually occur in multiple 
repeats or in combination with other RBDs; for example, RRMs, KH 
domains, zinc-finger domains or cold-shock domains recognize a 4–
6‑nucleotide mRNA sequence and predominantly occur in 
combinations or repeats, thus increasing sequence specificity and 
affinity of RBPs; Pumilio (Puf) motif binds one nucleotide, staking of 
this motif into a domain allows the binding of 8 nucleotides3. A list of 
the most common RBDs identified so far is reported in Table 1. 
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Table 1. RNA-binding domains. List of the RBDs commonly found in RBPs by 
Gerstberger et al. (2014) Nat Rev Genet. 15(12):829-45.
Introduction 
 
7 
 
RBPs can also be classified based on their RNA targets (Fig. 1). This 
type of classification also suggests the post-transcriptional pathways 
in which they are involved. 
 
 
 
 
Figure 1. RBPs classification. RBP families can be grouped according to their 
respective targets: ribosomal proteins, mRNA, tRNA, pre-ribosomal RNA, small 
nuclear RNA (snRNA), small nucleolar RNA (snoRNA), non-coding RNA 
(ncRNA); diverse targets and unknown targets (Gerstberger et al (2014) Nat Rev 
Genet. 15(12):829-45). 
 
The diversity of RBDs suggests that many RBPs remain yet to be 
identified. Accordingly, hundreds of novel non-canonical RBPs have 
been recently identified. These newly identified proteins are involved 
in diverse biological processes and belong to different protein 
families. Interestingly, many of them exhibit enzymatic activities, thus 
suggesting the existence of a crosstalk between RNA biology and 
other fundamental cell processes such as metabolism4. Unexpectedly, 
hundreds of the newly identified RBPs do not contain any of the 
classical RBDs, but they rather bind to RNA through the presence of 
intrinsically disordered protein regions in their sequence, that can be 
grouped into RS-rich, RG-rich, and other basic sequences, which 
mediate both specific and non-specific interactions with RNA5. These 
recent results confirm that the repertoire of RBPs is much higher than 
expected, probably because eukaryotes evolved highly specific post-
transcriptional processes to fine-tune gene expression, a process in 
which RBPs act as main players6. 
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1.2. RNA-binding proteins and the re-programming of gene 
expression in cancer 
Each cellular process – such as proliferation, differentiation, 
development, apoptosis, senescence, carcinogenesis - relies on the re-
programming of gene expression7. Although initially described as a 
“simple” three-step process, by which the flow of genetic information 
proceeds from DNA, passing through RNA, to the final protein, it is 
now clear that gene expression is more complex than expected and 
can be regulated at multiple levels8. Post-transcriptional control, that 
influence mRNA metabolism and translation once it is transcribed, 
represents one of the most intricate layer of gene regulation; therefore, 
it is not surprising that in pathologies such as cancer, cells strongly 
rely on this mechanism to adapt to the microenvironmental changes to 
support tumour growth and progression9. 
This complex layer of regulation involves spatially and temporally 
separated - but deeply integrated - mechanisms, that requires the 
intervention of hundreds of players10. 
RNA-binding proteins are considered one of the key players of post-
transcriptional control (Fig. 2). Through the interaction with other 
proteins and coding/non-coding RNAs, they form ribonucleoprotein 
complexes that are involved in every aspect of RNA biology, from 
pre-mRNA splicing and polyadenylation to RNA modification, 
transport, localization, and translation11. Given their pivotal role in 
post-transcriptional events, it is common that alterations of RBPs can 
lead to several diseases such as muscular atrophies, neuropathies and 
cancer12.  
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Figure 2. Overview of the complex life of a eukaryotic mRNA. A plethora of 
RNA-binding proteins guides the mRNA through multiple nuclear and cytoplasmic 
processing steps, which ultimately determine its fate and function in the cell 
(https://www.bmls.de/Computational_RNA_Biology/aboutus.html). 
 
Accordingly, several and recent studies provided strong evidence that 
RBPs can be abnormally expressed in cancer in comparison to 
adjacent normal tissues, and this expression directly correlates with 
patient prognosis13,14,15. 
For example, the RBP SAM68 is upregulated in breast cancer and its 
knockdown inhibits cell proliferation through the upregulation of the 
cell-cycle inhibitors p21 and CDKN1B/p27, at both mRNA and 
protein levels16. In a similar way, the transcription factor E2F1 
increases the mRNA levels of the RBP Quaking (QKI) which, in turn, 
negatively regulates E2F1 activity, delaying S-phase entry by 
increasing the stability of p27 mRNA and decreasing FOS mRNA 
expression in colon cancer17. Another well-studied family of RBPs 
overexpressed upon malignant transformation, are the insulin-like 
growth factor 2 mRNA binding proteins (IGF2BP). The expression of 
these proteins often correlates with poor prognosis. Overexpression of 
IGF2BP increases Myc and KRAS expression in colorectal cancer cell 
lines with increased proliferation, and its intestine deletion in a mouse 
model of intestinal tumorigenesis is responsible for the reduction of 
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tumour number18,19. The RBP Hu-antigen R (HuR) either promotes the 
translation or enhances the stability of several mRNA targets encoding 
pro-survival proteins such as BCL2, MCL1, PTMA, and SIRT1 in 
several malignancies20. In line with these results, deletion of HuR in a 
transgenic murine model leads to apoptosis of progenitor cell 
populations of intestinal systems21. In a similar way, La 
ribonucleoprotein domain family member 3 (LARP3) binds and 
enhances the translation of BCL2, MDM2, and XIAP mRNAs, 
promoting cell survival in myeloid leukemia22. Moreover, RBPs 
mediate different post-transcriptional events related to motility and 
invasiveness that are altered in cancer cells. An example is the RBP 
upstream of N-Ras (UNR), which was very recently demonstrated to 
be overexpressed in melanomas where it promotes invasion and 
metastasis through a translational regulation of its pro-metastatic 
target mRNAs, VIM and RAC115. 
Taken together, these studies provide strong evidence that the post-
transcriptional regulation of gene expression exerted by RBPs might 
be involved in every process leading to tumour development - usually 
through the dysregulation of their mRNA targets - from the evasion of 
cell death to the deregulated proliferation and invasion. 
 
1.3. Dysregulated RBP-dependent post-transcriptional 
mechanisms in cancer 
As mentioned above, RBPs act as main regulators of each step of the 
mRNAs life cycle, including alternative splicing, polyadenylation, 
stability, subcellular localization, and translation. Therefore, their 
roles in cancer can be attributed to the functional dysregulation of one 
or more of these post-transcriptional mechanisms. 
 
1.3.1. Alternative splicing 
Alternative splicing is a commonly altered mechanism in cancer, 
therefore the interest in targeting the spliceosome machinery has 
grown over the years23. The most frequent alterations of this process 
are attributable to altered RBPs function. Among the well-known and 
characterized RBPs families involved in alternative splicing there are 
the heterogeneous ribonucleoproteins particles (hnRNPs) and the 
serine/arginine-rich (SR) proteins24. Both proteins are dysregulated in 
a wide range of cancers25,26,27. Another splicing factor frequently 
downregulated in lung cancer, which is associated with poor 
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prognosis, is the QKI. QKI is a signal transduction and activators of 
RNA (STAR) family member that, in normal cells, selectively 
represses the inclusion of exon 12 in the NUMB mRNA by a 
competitive mechanism with the splicing factor SF1, thus promoting 
the expression of a NUMB mRNA isoform that inhibits proliferation 
by negatively regulating the Notch pathway (Fig. 3)28. In a similar 
way, the splicing factor RBM10 is downregulated in lung 
adenocarcinomas, where it promotes NUMB mRNA exon 9 skipping, 
leading to the expression of a NUMB isoform that blocks proliferation 
by inhibiting Notch pathway29. 
 
 
 
Figure 3. Alternative splicing. In cancer cells, QKI is frequently downregulated, 
leading to the expression of a NUMB mRNA isoform with exon 12 encoding a 
protein which is able to activate the Notch pathway and cell proliferation (Pereira B 
et al (2017) Trends Cancer. 3(7):506-528). 
 
1.3.2. Alternative polyadenylation 
Another crucial step in the processing of eukaryotic pre-mRNAs, is 
the addition of a poly(A) tail to their 3’-end by the endonucleolytic 
cleavage of the transcript and the addition of a stretch of adenosines. 
This step is required for nuclear export and to ensure mRNAs stability 
and efficient translation30. RBPs are also in charge for this process. As 
for the alternative splicing, alternative polyadenylation (APA) is 
responsible for the existence of multiple transcripts from a single 
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gene. APA can alter either the coding sequence - affecting the 
function of the protein product - or the 3’ untranslated region (3’-
UTR) - affecting the stability, localization, and translation of the target 
mRNA31. Hence, it is not surprising to find that APA is frequently 
altered in cancer. Cancer cells mostly express mRNA isoforms with 
shorter 3’-UTR, with consequent loss of 3’-UTR repressive elements 
that leads to the production of tenfold more protein in transformed 
cells by APA32. A well characterized family of RBPs involved in this 
process is the cytoplasmic polyadenylation element binding (CPEB) 
proteins family. For example, CPEB4 is overexpressed in melanomas, 
glioblastomas, and pancreatic ductal adenocarcinomas33,34. In 
melanomas, this protein controls polyadenylation and increased 
translation of MITF and RAB72A, targets involved in the G1/S 
transition, thereby promoting proliferation34. In pancreatic cancer, 
CPEB4 controls poly(A) tail elongation and abnormal translational 
activation of mRNAs that are silenced in normal tissue, including the 
mRNA of tissue plasminogen activator (TPA), thus promoting tumour 
growth, invasion, and vascularization (Fig. 4)33. Recently, it has been 
demonstrated a coordinated and sequential post-transcriptional role in 
the regulation of vascular endothelial growth factor (VEGF), by 
CPEB4 and CPEB1. Briefly, in transformed endothelioma cells, 
CPEB1 generates shorter 3’-UTR isoforms of both CPEB4 and VEGF 
mRNAs, thus excluding translation inhibitory elements. This trigger 
CPEB4 transcript stabilization and protein expression which, in turn, 
increases the translation of VEGF mRNA by enhancing its 
cytoplasmic polyadenylation35. 
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Figure 4. Alternative polyadenylation. CPEB4 is overexpressed in cancer cells 
and induces poly(A) tail elongation and translational activation of the TPA 
transcript, which supports tumour growth, invasion, and vascularization (Pereira B 
et al (2017) Trends Cancer. 3(7):506-528). 
 
1.3.3. mRNA Stability 
In addition to the poly(A) tail, eukaryotic mRNAs also incorporate a 
5’-cap structure during their biogenesis. This structure represents 
another element responsible for the regulation of mRNAs along with 
the 3’-poly(A). mRNAs must be cleaved by an endonuclease 
recognizing specific cis-destabilizing elements of one of these 
structures to drive them towards decay36. Among these elements, the 
most frequent in the 3’-UTR is the AU-rich element (ARE), which is 
found in about 16% of all transcripts37. In response to several stimuli, 
ARE elements are recognized by a family of RBPs known as ARE-
binding proteins (AUBPs). AUBPs are required for both the 
destabilization or the stabilization of the target transcript according to 
the cellular signals. 
The importance of mRNA stability and AUBPs in cancer is pointed 
out by the evidence that oncogenes, growth factors, cell-cycle genes, 
and inflammatory mediators are over-represented among the ARE-
containing transcripts38. For example, HuR is overexpressed in 
multiple cancer types, where it is responsible for increased 
proliferation by enhancing the stability of several ARE-containing 
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mRNAs. Among them, cyclins A1 and B in colorectal cancer, cyclin 
D1 in human cervical carcinoma, and cyclin E1 in breast 
cancer39,40,41(Fig. 4). Another example is the RNA-binding protein 
hnRNPD or AUF1, which has either stabilizing or destabilizing effects 
in different systems. A specific isoform of this protein, named 
p37AUF1, is able to induce spontaneous sarcomas when 
overexpressed in mice and leads to the accumulation of cancer-
associated transcripts like Myc, Fos and cyclin D142. Conversely, 
AUF1 can also act as a tumour suppressor by destabilizing mRNAs 
encoding the anti-apoptotic protein BCL2 and the proinflammatory 
factors GM-CSF, IL-6, IL-10, and TNF-α43. 
 
 
 
Figure 4. mRNA stability. HuR stabilization of the anti-apoptotic BCL2 ARE-
containing mRNA, eliciting survival. In its absence, the transcript is destabilized and 
targeted for decay by a process involving poly(A) tail shortening (Pereira B et al 
(2017) Trends Cancer. 3(7):506-528). 
 
1.3.4. mRNA localization and translation 
RBPs also play a major role in the intracellular localization - and 
consequent translation - of mRNAs by binding to sequences located in 
their 3’-UTR. Usually, RBPs associate with mRNAs and form multi-
complexes that link transcripts to cytoskeletal molecular motors, 
which, in turn, send RNPs to specific subcellular addresses44. 
Transporting mRNAs rather than proteins is significantly 
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advantageous for a cell for several reasons: i) a single mRNA can be 
translated in more protein molecules, so the transport of one mRNA 
instead of multiple proteins is cost-effective; ii) the mRNAs transport 
prevents proteins from carrying out their functions before reaching 
their final destination, where such function is actually required; iii) 
localized translation facilitates the incorporation of proteins into 
macromolecular complexes by generating high local protein 
concentrations of different subunits, as demonstrated for the seven 
members of the Arp2/3 complex, whose localized synthesis increases 
the chances of subunits finding each other for assembly45. These 
processes allow the fine-tuning of gene expression in both space and 
time; therefore, it is not surprising that this mechanism is frequently 
altered in cancer. 
Almost all the major oncogenic signalling pathways altered in cancer, 
such as PI3K/AKT/mTOR, RAS/MAPK, and Wnt/b-catenin lead to 
dysregulation of translation. The presence of sequence-specific 
regulatory elements in the mRNAs guides the preferential translation 
of the oncogenic program in cancer46. Among them, the internal 
ribosome entry site (IRES) - a structural element that can be found 
either in the 5’-UTR or the coding region, thereby triggering to the 
synthesis of different isoforms - is one of the most studied. IRES 
elements promote translation by recruiting the ribosome through an 
association with IRES trans-acting factors when cap-dependent 
translation is inhibited, a condition frequently found in tumours47. 
Several RBPs play a major role in both the transport and translation of 
their target mRNAs. For example, LARP3 interacts with the laminin 
B1 IRES, positively modulating its translation, which in turn enhances 
the epithelial to mesenchymal transition (EMT) programme that 
promotes the survival and invasiveness of hepatocellular cancer 
cells48. 
One of the best example of an RBP involved in both the transport and 
localized translation of its targets is provided by the insulin-like 
growth factor 2 mRNA binding protein 1 (IMP1), a member of the 
conserved VICKZ family of RBPs. IMP1 binds to actin B (ACTB) 
transcript in the nucleus and inhibits its translation in the cytoplasm 
(Fig. 5). ACTB translation occurs only when the RBP/mRNA 
complex reach the periphery of the cell, following the phosphorylation 
of IMP1 by Src-kinase - whose activity is spatially restricted - in a 
specific residue responsible for the RNA binding49. IMP1 is highly 
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expressed in primary tumour tissues like breast, colon and lung 
carcinomas, whereas it is downregulated in metastatic cells, and this 
downregulation impairs the transport and localized translation not 
only of ACTB but of other motility-related target mRNAs, such as α-
actinin, E-cadherin and the Arp2/3 complex, thus promoting cell 
migration and metastatic cells growth50,51. 
 
 
 
Figure 5. mRNA subcellular localization and translation: IMP1 protein 
recognizes specific sequences in the 3’-UTR of the β-actin mRNA, controlling its 
transport and subsequent translation in polarized cells. In cancer, dysregulation of 
this process impacts on the turnover of focal adhesions and protrusion dynamics, 
and this plays an important role in generating cells with a more motile and invasive 
behaviour (Pereira B et al (2017) Trends Cancer. 3(7):506-528). 
 
All these control events may act independently from one another or be 
coordinated in space and time, allowing RBPs to fine-tune gene 
expression in cancer. In some cases, a single RBP is involved in the 
regulation of a set of targets within specific post-transcriptional layers, 
while, in others, the combinations of two RBPs regulate a single 
transcript, which, depending on synergistic and/or antagonistic 
interplay, can yield different outcomes52. 
 
 
 
Introduction 
 
17 
 
1.4. Translational control in cancer: role of the ribosome-bound 
chaperones 
Among the aforementioned mechanisms, mRNA translation 
represents one of the main dysregulated processes in cancer cells, 
which exhibit an increase of protein synthesis and selective translation 
of specific mRNAs that promote tumour cell survival, sustained 
proliferation, invasion and metastasis. Accordingly, the 
overexpression of several components of translation initiation 
machinery, such as eIF2α, eIF3a, b, c, h, eIF4A, eIF4G1 and eIF5A 
was shown to cause or to strongly correlate with different cancer 
types, such as melanoma, cervix, breast, testis, prostate, 
hepatocellular, squamous cell lung and ovarian cancer53. Together 
with initiation factors, the overexpression of elongation factor has 
been associated to cancer as well. For example, the overexpression of 
EF1A1 and EF1A2 has been found in ovarian and breast cancer54. 
In eukaryotes, translation consist of three steps: initiation, elongation 
and termination. Accumulation of errors - usually associated to 
genetic instability - during each of these steps, can be responsible for 
the onset and progression of malignancies through the increased 
production of damaged and/or misfolded proteins, which is now 
considered a hallmark of cancer cells55. There are several sources that 
can generate defective translation products, therefore the ability of 
cells to detect and remove errors before the polypeptide is fully 
functional represents an opportunity to avoid their accumulation. To 
ensure the correct synthesis and folding of newly synthetized proteins, 
eukaryotic cells evolved protein quality control machineries, which 
also play crucial roles in cancer cells56. In this context, molecular 
chaperones are key players, being involved in the folding of both 
newly translated and stress-denatured proteins. While these processes 
are equivalent in prokaryotes - with chaperones associating equally to 
substrates generated either by synthesis or stress-denaturation - 
eukaryotes evolved a distinct and elaborate machinery of ribosome-
bound chaperones that interacts with and facilitates folding of nascent 
polypeptides in a co-translational manner57. Albanese et al 
demonstrated the existence of this machinery in yeast and referred to 
these translation-associated chaperones as Chaperones Linked to 
Protein synthesis (CLIPs). In line with this evidence, the so called 
“mammalian ribosome-associated complex” has been identified in 
higher eukaryotes. This complex comprises dynamically interacting 
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factors, including HSP70, serving multiple functions, such as co-
translational sorting, folding, and covalent modification of newly 
synthesized polypeptides58. 
When cell fails to remove errors, damaged proteins are targeted to 
degradation, mainly by the ubiquitin-proteasome system (UPS), which 
represents one of the major component of the quality control 
machinery, that can mark proteins for destruction while they are being 
synthesized59. Thus, both the chaperone network and the 
ubiquitination system are fundamental for the quality control of newly 
synthetized proteins, to ensure a correct folding and an efficient 
clearance of translation-defective products. By exerting a translational 
control on tumour-promoting/suppressing proteins, this complex 
protein quality control machinery is crucial for cancer development 
and progression. 
 
1.5. The molecular chaperone TRAP1 
TRAP1 (Tumour Necrosis Factor receptor-associated protein 1) is a 
molecular chaperone belonging to the heat shock protein 90 (HSP90) 
chaperone family - therefore also known as HSP75 -  with whom it 
shares 26% identity and 45% similarity60. Despite their similarity, 
TRAP1 and HSP90 do not share the same functions and show distinct 
features. While HSP90 exerts its function mainly in the cytoplasm, 
TRAP1 is mostly localized in mitochondria, where it contributes to 
protection from apoptosis induced by several stresses61. 
TRAP1 was discovered almost at the same time by two different 
groups: on one hand, it was identified as a type I tumour necrosis 
factor receptor-associated protein by a yeast-based two hybrid 
screening62, on the other hand it was characterized as a chaperone of 
the retinoblastoma protein63. 
TRAP1 is a protein that plays a controversial role in tumour biology. 
In fact, it was found strongly expressed in tumour cells of 
adenocarcinomas of pancreas, breast, colon, and lung, whereas normal 
matched epithelia contain very low levels of this chaperone64. 
Accordingly, this protein was found overexpressed in 17/26 human 
colorectal carcinomas65. It was also found abundantly and 
ubiquitously expressed in human high-grade prostatic intraepithelial 
neoplasia, Gleason grades 3 prostatic adenocarcinomas, and metastatic 
prostate cancer, but largely undetectable in normal prostate or benign 
prostatic hyperplasia in vivo66. Conversely, recent data show a more 
Introduction 
 
19 
 
complex scenario with a lower expression of TRAP1 in lung cancer 
and cisplatin-resistant ovarian cancer cells67,68,69. 
Although TRAP1 has been considered for long a mitochondrial 
protein and its functions investigated on the basis of this localization, 
it was firstly identified as non-mitochondrial62,63. Accordingly, extra-
mitochondrial localization of TRAP1 have been shown by electron 
microscopy70. Moreover, Ghosh et al. found it as a component of the 
membrane proteome71.  
 
1.5.1. TRAP1 outside the mitochondria: coupling of protein 
synthesis and degradation 
In line with such evidence, in 2012, our group performed a Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis, in 
which many cytoplasmic proteins were reported as putative TRAP1 
partners. Consistently, TRAP1 was found on the outer side of the 
endoplasmic reticulum (ER), opening a new scenario on the functions 
of this protein in cancer cells72. 
Our studies demonstrated that the endoplasmic reticulum TRAP1 
interacts with TBP7/Rpt3, an ATPase protein of the proteasome 
regulatory subunit. This interaction is involved in the co-translational 
protein quality control of nuclear encoded-mitochondrial proteins; in 
particular, the calcium binding protein Sorcin isoform B and 
F1ATPase β subunit. Both these proteins show lower expression and 
higher ubiquitination levels upon TRAP1 silencing in human 
colorectal cancer cells HCT116. Moreover, TRAP1 and/or TBP7 
interference increases total amount of ubiquitinated proteins. This 
phenotype can be attributed only to the extramitochondrial fraction of 
TRAP1, since the transfection of a TRAP1 mutant lacking the N-
terminal mitochondria targeting sequence – therefore unable to enter 
mitochondria – is able to rescue this phenotype72. The co-translational 
basis of this mechanism was suggested by the evidence that TRAP1 
associates with ribosomes and translational factors such as eIF4A, 
eEF1A and eEF1G. Consistently, few years ago, Pandolfi PP et al. 
identified a set of riboproteome components in mammalian cells 
through a SILAC-based mass spectrometry approach, in which they 
found TRAP1 as a component of the riboproteome73. Furthermore, our 
group demonstrated that in presence of TRAP1 there are enhanced 
phosphorylation levels of the translation factor eIF2α, both in basal or 
stress conditions, thus leading to the attenuation of cap-dependent 
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translation in favour of the IRES-dependent one. This mechanism 
prevents the accumulation of damaged or misfolded proteins and 
facilitates the synthesis of selective cancer-related proteins74. 
Accordingly, TRAP1 silencing sensitizes cells to apoptosis induced by 
novel antitumoral drugs that inhibit cap-dependent translation, such as 
Ribavirin or 4EGI-1, and reduces the ability of cells to migrate 
through the pores of transwell filters in the presence of these drugs75. 
Finally, TRAP1-dependent regulation of protein synthesis is involved 
in the migratory behaviour of different cancer cells by regulating 
p70S6 kinase expression and activity, and EMT associated genes76,77. 
 
 
 
Figure 6. TRAP1 outside the mitochondria. Overview of TRAP1 regulation of 
protein synthesis (Matassa DS et al (2017) Encyclopedia of Signaling Molecules, 
2nd Edition. ISBN: 978-3-319-67198-7). 
 
1.5.2. TRAP1 in mitochondria  
1.5.2.1. TRAP1 as an antiapoptotic protein 
According to its prevalent mitochondrial distribution and the great 
research interest in the characterization of TRAP1 mitochondrial 
functions, the first role assigned to this chaperone was the protection 
against mitochondrial apoptosis. In the mitochondria of tumour cells, 
TRAP1 is involved in a chaperone network that implies the formation 
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of a ternary complex - together with HSP90 and the immunophilin 
cyclophilin D - that regulates the permeability transition pore opening, 
maintaining mitochondrial homeostasis, and antagonizing the pro-
apoptotic function of cyclophilin D in permeability transition78. The 
mitochondrial TRAP1 also forms a cytoprotective complex with the 
mitochondrial isoform of the calcium-binding, antiapoptotic protein 
Sorcin in colorectal cancer cells79. Several observations suggest that 
oxidative stress prevention may be likely involved in (and part of) 
TRAP1 regulation of cell death. Accordingly, cells expressing high 
levels of TRAP1 show increased levels of the scavenging tripeptide 
GSH and are more resistant to oxidative stress, also showing cross-
resistance to chemotherapeutics65. Furthermore, TRAP1 prevents 
oxidative-stress-induced apoptosis in neurons as a downstream 
effector of PINK1, and the dysregulation of this mitochondrial 
pathway seems to be involved in the pathogenesis of Parkinson’s 
Disease (Fig. 7). In line with this evidence, TRAP1 overexpression 
causes a decrease of cleaved Caspase 3 and PARP, commonly 
considered as apoptotic markers. TRAP1 interference, as well as the 
use of dominant negative mutants of TRAP1, sensitized oxidative 
stress/chemoresistant cells to cell death inducers, thus providing the 
evidence that TRAP1 is an important player in the development and 
the maintenance of these phenotypes79. 
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Figure 7. TRAP1 in mitochondria. Overview of the antiapoptotic mechanisms in 
which TRAP1 is involved (Matassa DS et al (2017) Encyclopedia of Signaling 
Molecules, 2nd Edition. ISBN: 978-3-319-67198-7). 
 
1.5.2.2. TRAP1 as a modulator of cell metabolism 
In the last few years, TRAP1 has also emerged as a critical regulator 
of mitochondrial respiration through the direct binding to respiratory 
complexes80. Data showed that TRAP1 interact with complex II and 
IV of the electron transport chain and inhibits Succinate 
dehydrogenase (SDH) activity, without affecting complex II protein 
levels or mitochondrial mass, thus contributing to the Warburg 
phenotype81. As a result, TRAP1 yields a reduced oxygen 
consumption rate (i.e. reduced mitochondrial respiration) in different 
cell lines, thus inducing a metabolic shift toward glycolysis and a 
“Warburg phenotype”, and decreased fatty acid oxidation80. 
Conversely, another group found an interaction between TRAP1 and 
the tyrosine-protein kinase c-Src, which is known to stimulate 
complex IV activity and to enhance oxidative phosphorylation, 
suggesting that the impact of TRAP1 on mitochondrial respiration 
could be mediated by c-Src (Fig. 8)82. 
We have recently reported that TRAP1 reduces oxidative 
phosphorylation rate in ovarian cancer cells, but in such system 
oxidative phosphorylation favours drug resistance, thus providing to 
TRAP1 oncosuppressive properties in this specific context69. Taken 
together, these studies revealed that the regulation of cancer cell 
metabolism by TRAP1 seems to have contextual effects on cancer 
onset and progression, thus favouring the oncogenic phenotype in 
glycolytic tumours81, while being negatively selected in tumours 
mostly relying on oxidative metabolism69. 
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Figure 8. TRAP1 in mitochondria. Overview of cell metabolism modulation by 
TRAP1 (Matassa DS et al (2017) Encyclopedia of Signaling Molecules, 2nd 
Edition. ISBN: 978-3-319-67198-7). 
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2. AIM 
TRAP1 is a molecular chaperone involved in the quality control of 
mitochondria-destined proteins, through the regulation of their co-
translational ubiquitination and degradation. However, mechanisms of 
substrate recognition are still unknown. The question that gave rise to 
the present study is whether TRAP1 identify and binds some 
interacting partners through its interaction with RNA. Several lines of 
evidence suggest that TRAP1 might directly recognize and bind its 
substrates as mRNAs, being potentially involved in their transport to 
mitochondria and localized translation. In fact, some unpublished data 
by our group strongly supports this hypothesis, with an increase of 
actively translating ribosomes in the proximity of mitochondria 
following TRAP1 overexpression, as demonstrated by increased 
number of proximity ligation foci between the mitochondrial protein 
import channel Tom20 and active ribosomal protein phospho-rpS6 
(Fig. 9). 
 
 
 
Figure 9. TRAP1 overexpression increases protein synthesis in the vicinity of 
mitochondria. 24 hours after induction, HeLa eGFP and TRAP1-eGFP were fixed, 
permeabilized and hybridized with anti-TOM20 and anti-phospho rpS6 antibodies 
and subjected to proximity ligation assay (PLA). PLA allows visualization of 
distinct fluorescent spots (red points) when the two target epitopes are distant no 
longer than 40 nm. Nuclei were stained with DAPI (blue). 
 
Moreover, it has been previously demonstrated that TRAP1 binds the 
3’-UTR of the mitochondrial ribosomal protein S1283. Finally, TRAP1 
was identified as a putative RBP in HeLa cells, following the 
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interactome capture technique developed by Castello A. and 
colleagues4. 
TRAP1 substrates recognition mechanisms could also involve other 
players. Accordingly, preliminary analyses by mass spectrometry 
revealed that some TRAP1 interactors are validated or putative RBPs. 
Among those, we focused our attention on Protein Syndesmos 
(SDOS)/Nudt16l1 a paralog of the nuclear Nudt16, but lacking the 
catalytic activity due to critical sequence changes within the catalytic 
NUDIX domain and therefore unable to perform its canonical mRNA 
decapping activity84. Although initially described for its role in the 
assembly of focal adhesions and actin stress fibers - through the 
interaction with Syndecan4, Paxillin and its homolog Hic-585 - a very 
recent and interesting research demonstrated that SDOS plays a role in 
DNA damage response. In fact, it interacts with the Tudor domain of 
the P53-binding protein 1 (53BP1) influencing its function during 
double-strand break repair by masking its demethylated lysine 20 of 
histone H4 binding motif86. Interestingly, SDOS as well was found in 
the list of the HeLa RBPs repertoire identified by interactome capture, 
strongly supporting the hypothesis that SDOS and TRAP1 might have 
RNA-binding properties. 
 
Starting from these observations, and more specifically, the aim of my 
study is to: 
• Characterize TRAP1/SDOS interaction; 
• Analyse SDOS localization and functions in cancer cells; 
• Demonstrate that TRAP1 and/or SDOS are RBPs; 
• Identify TRAP1 and SDOS-directly regulated targets; 
• Identify and characterize relevant pathways affected by 
TRAP1 and SDOS, based on the identified substrates.
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3. MATERIALS AND METHODS 
3.1.  Cell culture  
Human HCT116 colon carcinoma cells and human cervical carcinoma 
HeLa cells were purchased from American Type Culture Collection 
(ATCC) and cultured in McCoy's 5A medium (HCT) and DMEM 
(HeLa). Both culturing mediums contain 10% fetal bovine serum, 1.5 
mmol/L glutamine. The authenticity of the cell lines was verified at 
the beginning of the project by STR profiling, in accordance with 
ATCC product description. HeLa Flp In TRex (FITR) cell line were 
kindly provided by Dr. Matthias Gromeier (Duke University Medical 
Center, Durham, USA). Generation of the HeLa Flp In TRex stable 
cell lines expressing the eGFP-fusion proteins or the short hairpin 
RNA, was performed as described in the manufacturer’s protocol (Flp 
In TRex, Invitrogen). HeLa Flp In TRex cells were cultured in 
DMEM supplemented with 10% fetal bovine serum, 1.5 mmol/L 
glutamine, and appropriate selective antibiotics. Addition of 
tetracycline induces proteins as described in4. 
 
3.2. Plasmid generation and transfection procedures 
Full-length SDOS-myc cloned into pcDNA 3.1 myc-his vector was 
obtained as previously described72. MOV10-YFP and eGFP alone 
cloned into pcDNA5/FRT/TO (Invitrogen) were kindly provided by 
Prof. Matthias Hentze, EMBL/Heidelberg Univ. “Molecular Medicine 
Partnership Unit”. For TRAP1-eGFP and SDOS-eGFP plasmids 
generation, HeLa cDNA library and eGFP plasmid were used as 
templates for fusion PCR. Resulting chimeric cDNAs were cloned 
into pCDNA5/FRT/TO. TRAP1-Flag-HA and SDOS-Flag-HA 
plasmids were obtained in the same way by using the Flag-HA tagged 
vector as template kindly provided by Dr. Alfredo Castello, 
Department of Biochemistry, University of Oxford. Transient 
transfection of DNA plasmids was performed with the Polyfect 
Transfection Reagent (Qiagen - 301105) according to the 
manufacturer's protocol. TRAP1 and SDOS transient silencing were 
performed with siRNAs purchased from Qiagen (TRAP1: cat. no. 
SI00115150; SDOS: cat. no. SI00713293). For control experiments, 
cells were transfected with a similar amount of scrambled siRNA 
(Qiagen; cat. no. SI03650318). Transient transfections of siRNAs 
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were performed using HiPerFect Transfection Reagent (Qiagen - 
301704) according to the manufacturer's protocol. 
 
3.3. Western blot and Immunoprecipitation analysis 
Equal amounts of protein from cell lysates was subjected to SDS-
PAGE and transferred to a PVDF membrane (Millipore). WB analysis 
were performed as described in87. Protein immunoprecipitations were 
carried out as previously described74. eGFP-fusion proteins were 
immunoprecipitated with GFP_trap agarose beads (GFP_trapA: 
Chromotek) according to manufacturer’s instructions. Where 
indicated, protein levels were quantified by densitometric analysis 
using the software ImageJ. The following antibodies were used for 
WB, immunofluorescence and immunoprecipitation: anti-TRAP1 (sc-
13557), anti-β-ACTIN (sc-69879), anti-GAPDH (sc-69778), anti-Bip 
(sc-1051), anti VDAC1 (sc-8828), anti-F1ATPase (sc-16690), anti-
eGFP (sc-81045), anti-MYC (sc-40), anti-Vinculin (sc-73614), anti-
PARP1 (sc-25780); anti-SDOS (HPA044186), anti-FLAG (FT425), 
anti-TMEM107 (HPA052555) from Sigma-Aldrich; anti-PABP1 
(GTX113954) from Genetex; anti-rpL3 was kindly provided by Prof. 
Giulia Russo, Department of Pharmacy, University of Napoli 
“Federico II”. 
 
3.4. RNA extraction and qPCR analysis 
RNA extraction procedures and qPCR analysis were performed as 
described in72. 
 
3.5. 35S Met/35S Cys labelling  
HeLa FITR and HCT116 cells were seeded in a 6-well plate. HeLa 
eGFP and HeLa SDOS-eGFP cells were induced for 24 hrs while 
HeLa sh-eGFP and sh-SDOS for 48 hrs with 1 μg/mL doxycycline. 
HCT116 were transfected with a SDOS-directed siRNA. For control 
experiments, cells were transfected with a similar amount of non-
targeting control siRNA. Following proteins induction or silencing, 
cells were incubated in cysteine/methionine-free medium (Sigma-
Aldrich) for 15 min followed by incubation in cysteine/methionine-
free medium containing 50 µCi/ml 35S-labeled cysteine/methionine 
(Perkin-Elmer) for 30 min. Cells were then washed with PBS and 
lysed. Ten µg of total protein extract was analysed by SDS-PAGE and 
autoradiography. 
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3.6. Confocal microscopy and Fluorescence in situ hybridization 
analysis (FISH) 
HeLa SDOS-eGFP cells were seeded on coverslips and prepared for 
immunofluorescence analysis as previously described76 following 
Sodium Arsenite treatment. For FISH analysis, cells were directly 
grown onto coverslips. Following Sodium Arsenite treatment, cells 
were washed once with PBS and fixed in 4% paraformaldehyde for 10 
minutes at room temperature. Cells were then permeabilized by 
treatment with 100% Ethanol for 10 minutes, rehydrated with 70% 
Ethanol and equilibrated in TRIS-HCl pH 8 for 10 minutes. 
Hybridization was performed 2 hrs at 37°C in 30 µl of a mixture 
containing 10% dextran sulphate, 2 mM vanadyl-ribonucleoside 
complex, 1% RNAse-free BSA, 0,5 µg/µl of E. coli tRNA, 2X SSC, 
20% formamide, 2 ng/µl of Alexa-594 oligo-dT probe. Cells were 
then washed once with SSC 4X for 10 minutes, twice with SSC 2X for 
ten minutes, and once with SSC 2X containing 0,1% Triton for 15 
minutes followed by two more washes with SSC 2X. Coverslips were 
mounted with appropriate mounting medium and signal was detected 
by confocal microscopy analysis. 
 
3.7. Duolink in situ proximity ligation assay 
Duolink in situ proximity ligation assay (Sigma-Aldrich - DUO92101) 
was performed according to the manufacturer’s instructions. Briefly, 
cells were seeded on coverslips, fixed, permeabilized and hybridized 
o.n. with anti-TRAP1 and anti-SDOS antibodies. Next day cells were 
hybridized with secondary antibodies conjugated with the PLA probes 
(PLUS and MINUS), and then subjected to ligation and rolling circle 
amplification using fluorescently labelled oligonucleotides. Cells were 
washed and mounted on slides using a mounting media with DAPI to 
detect nuclei and signal was detected by confocal microscopy 
analysis. 
 
3.8. Cell fractionation 
Mitochondria and ER were purified by using the Qproteome 
Mitochondria Isolation kit (Qiagen - 37612) according to the 
manufacturer’s protocol. For the collection of ribosomal and non-
ribosomal fractions, the lysates were centrifuged at 10,000 × g at 4°C 
for 15 min in order to remove the mitochondria and cell debris. The 
supernatant was layered over a sucrose (20% wt/vol) cushion 
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containing cycloheximide and centrifuged at 149,000 × g for 2 h. The 
pellet containing ribosomes and the upper and lower pellets of the 
non-ribosomal supernatants were collected. The ribosomal pellets 
were resuspended in the lysis buffer, after which immunoblotting was 
performed. Nuclear fractions were purified according to the 
manufacturer’s protocol (Abcam). 
 
3.9. PNK assay 
Cells expressing eGFP-fusion proteins were UV-crosslinked on ice 
(150 mJ/cm2), lysed (100mM KCl; 5mM MgCl2, 10mM Tris pH 7.5, 
0.5% NP40; 1mM DTT; protease inhibitor cocktail), and 
homogenized passing the lysate through a narrow needle (22G) 
followed by pulsed ultrasonication (3 × 10 s, 50% amplitude, on ice). 
Cleared lysates were treated with 50 U/ml DNAseI (Takara) and 
RNaseI for 15 min at 37 °C, and used for immunoprecipitation with 
GFP-Trap®_A agarose beads (Chromotek) for 2h at 4°C. Beads were 
washed four times with High salt buffer (500mM NaCl, 20mM Tris 
pH 7.5, 1mM MgCl2, 0,05% NP40, 0,1% SDS, complete) and two 
times with PNK buffer (50 mM Tris pH 7.4, 50 mM NaCl, 10 mM 
MgCl2, 0.5% NP-40, 5 mM DTT). RNA crosslinked to the tagged 
RBP is identified by radiolabeling with 0.1 μCi/μl γ-32P ATP by T4 
polynucleotide kinase (1U/μl) in PNK buffer (50 mM NaCL, 50 mM 
Tris pH 7.5, 0.5% NP-40, 10 mM Mg2Cl and 5 mM DTT) for 15 min 
at 850 rpm and 37°C. Beads were washed four to six times with PNK 
buffer and protein-RNA complexes were eluted by boiling samples 5 
minutes at 95°C. Samples were analysed by SDS PAGE and 
autoradiography. For Flag-HA fusion proteins expressing cells the 
protocol described in91 was followed. 
 
3.10. Interactome capture for eGFP-tagged proteins 
1x15 cm plate of eGFP-fusion protein expressing cells was induced 
for 24 hrs (TRAP1) and 16 hrs (SDOS and eGFP) with 1 μg/mL 
doxycycline. TRAP1-eGFP and SDOS-eGFP cells were treated with 
100 μM 4-thiouridine overnight and photoactivatable ribonucleoside-
enhanced cross-linked (PAR-CL) on ice at 0.60 and 0.30 J cm−2 with 
UV light at 365 nM. Following UV-irradiation the protocol was 
performed as previously described (Strein C. et al., 2014).  
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3.11. Polysome profiling 
3x10 cm plates of cells were incubated 15 min at 37°C with fresh 
medium supplemented with 100 μg/ml of cycloheximide (Sigma). 
Cells were then washed with ice cold PBS supplemented with 100 
μg/ml cycloheximide and resuspended in 1 mL lysis buffer (10 mM 
Tris-HCl pH7.4, 100 mM KCl, 10 mM MgCl2, 1% Triton-X100, 2 
U/ml Turbo DNase (Ambion), 2 mM DTT, 10 U/ml Ribolock 
(Invitrogen), 100 μg/ml of cycloheximide). Glass beads (Sigma-
Aldrich; G8772) were added to the lysate and cells were broken by 
vortexing at medium speed for 3 pulses of 10 s. After 5 min of 
incubation on ice, cell lysate was centrifuged for 5 min at 5000 rpm at 
4°C. The supernatant was collected, and the absorbance was measured 
at 260 nm with the NanoDrop. Eight A260 units were loaded onto a 
10-50% sucrose gradient obtained by adding 6 ml of 10% sucrose 
over a layer of 6ml 50% sucrose prepared in lysis buffer without 
Triton and containing 0.5 mM DTT, in a 12-mL tube (Polyallomer; 
Beckman Coulter). Gradients were obtained with the help of a 
gradient maker (Gradient Master, Biocomp). Polysomes were 
separated by centrifugation at 35000 rpm for 3 hrs using a Beckmann 
SW41 rotor. Eleven fractions of 1 mL were collected while polysomes 
were monitored by following the absorbance at 254 nm. Total protein 
was retrieved by 100% ethanol precipitation performed overnight and 
analysed by SDS-PAGE followed by Western blot.  
 
3.12. Ribosome profiling 
Ribosome profiling was performed according to the protocol 
described in (Ingolia N et al., 2012). Briefly, unfused eGFP, TRAP1-
eGFP and SDOS-eGFP cells were cultured in 15 cm plates and 
induced with doxycycline for 24 hrs. After 15 min incubation with 
100 μg/ml cycloheximide (Sigma-Aldrich; C4859) at 37°C, cells were 
washed with ice cold PBS and 1 mL of lysis buffer (20 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 μg/ml 
cycloheximide, 1% Triton-X100) was added. Cells were then 
collected and incubated on ice; glass beads (Sigma-Aldrich; G8772) 
were added to the lysate and cells were broken by vortexing at 
medium speed for 3 pulses of 10 s. After 10 min of incubation on ice, 
lysates were centrifuged for 10 min at 10000 rpm at 4°C, and the 
supernatant was recovered. RNA was partially digested with 3.5 μl of 
RNase I (100 U/μl, Invitrogen AM2294) per 800 μl of lysate. After 15 
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min of incubation at 24°C, lysates were placed on ice and 
supplemented with 10 μl of SUPERaseIn (20 U/μl, Invitrogen 
AM2694). Lysates were then loaded on a 34% sucrose cushion (34% 
sucrose in 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 
mM DTT and 100 μg/ml cycloheximide) and monosomes were 
pelleted by centrifugation for 1 hr at 70000 rpm using a Beckman 
TLA 100.3 rotor. RNA was extracted from the pellet and ribosome 
protected fragments (RPFs) of 30 nucleotides were purified as 
described (Ingolia N et al., 2012). RPFs were depleted of ribosomal 
RNA with the Ribo-Zero rRNA removal kit (Epicentre MRZH116) 
according to manufacturer’s indications. cDNA libraries were 
generated according to (Ingolia N et al., 2012) and sequenced by 
Solexa using a HiSeq 2000, Single Read, 50 nt at the CRG Genomics 
Core Facility, Barcelona, Spain. 
 
3.13. eCLIP-inspired individual nucleotide cross-linking 
and immunoprecipitation (iCLIP)-seq 
1x15 cm plate of eGFP-fusion protein expressing cells was induced 
for 24 hrs (TRAP1) and 16 hrs (SDOS and eGFP) with 1 μg/mL 
doxycycline. TRAP1-eGFP and SDOS-eGFP cells were treated with 
100 μM 4-thiouridine overnight and photoactivable ribonucleoside-
cross-linked on ice at 0.60 and 0.30 J cm−2 with UV light at 365 nM.  
Immediately after irradiation, cells were lysed in 1 mL of lysis buffer 
(NaCl 100mM, MgCl2 5mM, Tris pH 7.5 10mM, NP40 0.5%, SDS 
0.1%, Na deoxycholate 0.5%, DTT 1mM (fresh), 1x AEBSF (fresh). 
The cell lysate was passed 3 times through 27 1/2G needle and 
sonicated using a bioruptor (Digenode) for 3 cycles of 10 seconds 
(pause 15 seconds), level M at 4ºC, then it was cleared by 
centrifugation at 17900g for 10 min at 4°C. RNA was then partially 
digested by adding 10 μl of 1:100 dilution of RNase I (Ambion, 
AM2295), as well as 2 μl of Turbo DNase (Ambion, AM 2238). After 
3 min of incubation at 37°C under shaking at 1100 rpm 11 μl of 
Ribolock (Invitrogen) were added to each lysate. The lysates were 
precleared by incubation with 50 µL of equilibrated control agarose 
beads (Thermo Scientific) for 30 min at 4°C under gentle rotation. 
eGFP-fusion proteins were then captured from precleared lysates by 
incubation with 40 µL of GFP-Trap agarose beads (GFP-Trap_A, 
Chromotek) per mL of lysate for 2 h, 4°C, gentle rotation. Beads were 
collected by centrifugation and washed twice with High salt buffer 
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(NaCl 500mM, Tris HCL pH7.5 20mM, MgCl2 1mM, NP40 0.05%, 
SDS 0.10%, 1x AEBSF (fresh)); twice with Medium salt buffer (NaCl 
250mM, Tris HCl pH7.5 20mM, MgCl2 1mM, NP40 0.05%, 1x 
AEBSF (fresh)) and twice with Low salt buffer (NaCl 150mM, Tris 
HCl pH7.5 20mM, MgCl2 1mM, NP40 0.01%, 1x AEBSF (fresh)). 
The RNA was dephosphorylated, and 3’-linker ligated as described 
in92. The protein/RNA complexes were isolated as described in93. 
Samples were processed for subsequent steps as described in92. cDNA 
libraries obtained after PCR amplification with universal Solexa 
primers (25 cycles) were multiplexed and sequenced using an Illumina 
Next-generation sequencing platform at Science for Life Laboratory at 
Karolinska Insitue, Solna, Sweden. 
 
3.14. RNA-seq from total RNA 
Raw signal intensity data from Illumina HumanHT-12_V4_0_R2 
microarrays normalized, batch effect removed, and low-quality 
annotation probes excluded. Differentially expressed genes (DEGs) 
and ranked (rnks) lists obtained by a moderated t-test on the linear 
model fit of the microarray data. DEGs with p-values <0.05 were 
retained. All the steps performed according to the “microarray 
analysis” best practice using R well known packages (R Core Team 
2017; Ritchie ME. et al, 2015). Intersection of the DEGs performed 
according to the experimental design (same or different Fold Change 
sign). 
 
3.15. GFP_trap immunoprecipitation and qPCR 
1x15 cm plate of SDOS-eGFP and eGFP control cells was induced for 
16 hrs with 1 μg/mL doxycycline. SDOS-eGFP cells were treated with 
100 μM 4-thiouridine overnight and photoactivable ribonucleoside-
cross-linked on ice at 0.30 J cm−2 with UV light at 365 nM. eGFP 
cells were cross-linked on ice at 0.15 J cm−2 with UV light at 254 
nM. Immediately after irradiation, cells were lysed in 1 mL of lysis 
buffer (NaCl 100mM, MgCl2 5mM, Tris pH 7.5 10mM, NP40 0.5%, 
SDS 0.1%, Na deoxycholate 0.5%, DTT 1mM (fresh), 1x AEBSF 
(fresh), 100 U/mL Ribolock RNase inhibitor, 200 µM ribonucleoside 
vanadyl complex). The cell lysate was passed 3 times through 27 1/2G 
needle and sonicated using a bioruptor (Digenode) for 3 cycles of 10 
seconds (pause 15 seconds), level M at 4ºC, then it was cleared by 
centrifugation at 17900g for 10 min at 4°C. 50 µl of input were used 
Materials and Methods 
 
33 
 
to measure fluorescence signal at plate reader in order to normalize 
the amount of eGFP proteins to be immunoprecipitated. 30 µl of 
control magnetic agarose beads (Pierce) and GFP_trapMA beads 
(Chromotek) were equilibrated in Dilution buffer (NaCl 500mM, 
MgCl2 1mM, SDS 0.05%, NP40 0.05%, Tris pH 7.5 50mM, 100 
U/mL Ribolock RNase inhibitor (fresh), 1x AEBSF (fresh)).  Lysates 
were pre-cleared for 30 min under rotation at 4°C with 30 µl of 
control magnetic agarse beads. GFP_trapMA were incubated with E. 
coli tRNA (1 mg/mL) for 15 min in dilution buffer under rotation at 
4°C and then washed 2 times with dilution buffer. Pre-cleared lysates 
were then incubated with GFP_trapMA beads for 2 hrs under rotation 
at 4°C. Beads were then washed 2 times with High salt buffer (NaCl 
500mM, Tris pH 7.5 20mM, MgCl2 1mM, NP40 0.05%, SDS 0.1%, 
Ribolock RNase inhibitor 100U/mL (fresh), 1x AEBSF (fresh) and 3 
times with Low salt buffer (NaCl 150mM, Tris pH 7.5 20mM, MgCl2 
1mM, NP40 0.01%, Ribolock RNase inhibitor 50U/mL). Beads were 
resuspended in 100 µl of Proteinase K buffer (NaCl 0.1M, Tris pH 7.5 
10mM, EDTA 1mM, SDS 0.5%, 200 µg/mL Proteinase K, 50 pg 
spike-in control RNA) and incubated at 55°C for 1 hr under costant 
mixing. To recover RNA, 100 µl of TRI Reagent were directly added 
to the buffer-containing beads followed by extraction and ethanol 
precipitation. The RNA was reverse transcribed, and the resulting 
cDNA was analysed by quantitative PCR. The amount of precipitated 
RNA from IPs was normalized to the amount of the spike-in control. 
 
3.16. Protein-protein interaction identification by MS 
1x15 cm plate of TRAP1-eGFP, SDOS-eGFP and unfused eGFP 
expressing cells was induced for 24 hrs with 1 μg/mL of doxycycline. 
Cells were then lysed with 1 mL of lysis buffer (NaCl 150 mM, Tris-
Hcl pH7.5 10 mM, Triton X-100 1%, MgCl2 5 mM, DTT 5mM (fresh) 
and AEBSF 1x (fresh)) on ice for 15 min. Lysates were cleared by 
centrifugation at 16000g for 5 min. Lysates were precleared by 
incubation with 50 µL of equilibrated control agarose beads (Thermo 
Scientific) for 30 min at 4°C under gentle rotation. eGFP-fusion 
proteins were then captured from precleared lysates by incubation 
with 40 µL of GFP-Trap agarose beads (GFP-Trap_A, Chromotek) 
per mL of lysate for 2 h, 4°C, gentle rotation. Beads were collected by 
centrifugation and washed six times with lysis buffer. Samples were 
eluted from the beads by pH elution as indicated in the manufacturer’s 
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protocol (GFP_trapA; Chromotek) and sent to the MS facility of 
Department of Biochemistry, University of Oxford, for the analysis. 
 
Bioinformatic Methods 
3.17. Bioinformatic analysis of iCLIP datasets 
Sequencing of the iCLIP libraries (75bp single-end reads) was carried 
out on an Illumina NEXTseq at the Karolinska Institutet, Solna, 
Sweden. We used the demultiplex script from the iCount pipeline 
(Curk et al., 2016, http://icount.readthedocs.io/en/latest/) to trim off 
adapter sequences, to extract sample and molecular barcodes, and to 
demultiplex. We then mapped the reads to the human genome and 
annotation version GRCh38 downloaded from ENSEMBL using 
splice-aware mode of the STAR aligner (Dobin et al., 2012) though 
the iCount script mapstar. We then removed the PCR duplicates and 
identified the crosslinked sites on RNA using xlsites and peaks from 
the iCount pipeline. The crosslinked base is identified as the last base 
of the cDNA and first base of the read after the barcodes in this 
protocol. We then defined binding regions on RNA using a window of 
10nt with BEDTools (Quinlan and Hall, 2010). Binding regions were 
then assigned to genes and transcript features based on their overlap 
with annotated transcript features (ENSEMBL version GRCh38) 
utilising R/Bioconductor package GenomicRanges (Lawrence et al., 
2013). We used the following assignment preference rule to assign 
those peaks that overlapped multiple annotated features at a gene 
level: protein coding exonic > miRNA > snRNA > snoRNA > rRNA 
> lincRNA > antisenseGenes > protein coding intronic > other > 
senseIntronic. Peaks overlapping multiple annotated exonic protein 
coding features were further assigned to transcript features according 
to the following assignment preference rule: CDS > 5UTR > 3UTR > 
other. In order to define reliable target genes for downstream analyses 
and experimental validation, we selected binding region with a False 
Discovery Rate < 0.05 and for which there was no signal detected for 
the gene in the negative control (eGFP) sample. 
 
3.18. Bioinformatic analysis of Ribosome Profiling datasets 
Raw sequence reads were demultiplexed and adapter remnants were 
trimmed using cutadapt (Martin M., 2011). 
Reads derived from rRNAs were filtered out after a first pass mapping 
using bowtie2 and a custom composite rRNA genome. Remaining 
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reads were aligned with Tophat2 on the hg38/GRCh38 human genome 
and the corresponding ENSEMBL transcriptome. Number of reads 
mapping “exon” was calculated with htseq-count (Anders S et al., 
2015) according to ENSEMBL annotation. Differentially expressed 
Ribosome Protected Fragments (RPFs) were calculated using the 
DEseq2 bioconductor R package (Love MI et al., 2014). For 
downstream analysis, we considered only RPFs with Fold Change > 
3.0. Selected RPFs were normalized to the Microarray results in order 
to select only those genes regulated at translational level. 
 
3.19. Gene Ontology Analyses 
iCLIP and RP data (significantly impacted pathways, biological 
processes, cellular component, diseases) were analysed using Advaita 
Bio’s iPathwayGuide (http://www.advaitabio.com/ipathwayguide). To 
highlight a possible activation/deactivation of biological functions and 
pathways the gene set enrichment analysis (GSEA) (Subramanian A. 
et al, 2005) of DEGs was performed for rnk each list. In particular, the 
analysis focused on hallmark, c2 and c5 gene sets collected by the 
Molecular Signatures Database (MSigDB) (Liberzon A. et al, 2015) 
 
List of Oligos 
 
Oligo name Oligo sequence (5'-3') 
CC2D2A FW AGGGGCATCTCCAACACTCA 
CC2D2A RV TCATTTTGGCTGGGATGGGT 
TMEM67 FW TGCCCAGAAAACATGAAAGGTG 
TMEM67 RV TCACAGAGCTCACAAGTTGCT 
NPHP1 FW TTGGAGCAGCCTGATGTGAT 
NPHP1 RV CTCTTCTTCTGCCCACCTGAA 
KIF7 FW ATGGAAACCTGACTGCCTGG 
KIF7 RV CAGTGGTCGAACTCGCAGG 
TTC21B FW GGCGAGACAATCCCCAGAG 
TTC21B RV CCTGAAGACTGGATCACTTCCA 
ZNF423 FW CATGGATGCATAAGAAGAGGGTTGA 
ZNF423 RV TGGTTTTCTGATCGCACTCTGG 
RPGRIP1L FW CATTTCCCAGGAGGCTACGG 
RPGRIP1L RV GTTGGACCAGACATGGCCTA 
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AHI1 FW GTGTCAACCTGGGGCTGAAT 
AHI1 RV ATGCAGAGGACTGAGAATGCAA 
TCTN1 FW GCACAACTGAGCAAGACTGC 
TCTN1 RV AAAGGGGCCACGTAATCTGG 
TOPORS FW CGACACCGACCTAGCTTTCT 
TOPORS RV GCTAGTGCCAGCTTTAGGTGA 
TMEM107 FW  CCCCGAGGAGTATGACAAGC 
TMEM107 RV  GCACTACAGTGAGCCCCAAT 
LUC FW  TACAACACCCCAACATCTTCGA 
LUC RV  GGAAGTTCACCGGCGTCAT 
ACTB FW CCTCACCCTGAAGTACCCCA 
ACTB RV TCGTCCCAGTTGGTGACGAT 
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4. RESULTS 
4.1. SDOS is a novel TRAP1-interacting partner 
A previous mass spectrometry analysis performed to identify the 
protein partners of TRAP1 in a proteome-wide manner allowed to 
identify, among the others, several mitochondrial and cytoplasmic 
proteins involved in different pathways, such as protein synthesis and 
post-translational modifications, cell cycle regulation, cell 
metabolism, trafficking and mRNA synthesis, transport and 
modification87. Among those, coherently with the aim of the study of 
further dissecting the molecular mechanisms involved in TRAP1 
regulation of its substrates, we focused our attention on the putative 
RNA-binding protein SDOS. In order to confirm that SDOS is indeed 
a TRAP1-interacting partner, we performed co-immunoprecipitation 
analysis. To this aim, TRAP1 was immunoprecipitated from HCT116 
cells 24 hrs after transfection of a SDOS-myc expressing construct. 
Results showed a specific co-IP band following blot with anti-myc 
antibody (Fig. 1A). TRAP1/SDOS interaction in HCT116 cells was 
further confirmed by proximity ligation assay, as shown in Fig. 1B. 
For our subsequent analyses, we took advantage of the “Flp-In™ T-
REx™” (FITR) System, which allows the generation of stable 
mammalian cell lines exhibiting tetracycline-inducible expression or 
silencing of a gene of interest from a specific genomic location, thus 
ensuring the integration in each cell of the population.  
Once established HeLa FITR cell lines expressing the eGFP-fusion 
proteins of interest, we performed a mass spectrometry analysis to 
confirm SDOS as a TRAP1-interacting partner in our model, and to 
ensure that the fused eGFP protein does not interfere with this 
interaction. TRAP1-eGFP and SDOS-eGFP were immunoprecipitated 
- immunoprecipitation of the unfused eGFP was used as a negative 
control - and analysed by mass spectrometry to look at the protein-
protein interaction. SP3 sample preparation method was used to 
maximise sensitivity, while “label free” quantification was used to 
compare the unfused eGFP control to the protein of interest. Results of 
the analysis demonstrated not only that SDOS is one the strongest 
TRAP1-interacting partners, but that TRAP1 was one of the strongest 
SDOS-interacting partner as well (Table 1). Neither TRAP1 nor 
SDOS were found in the eGFP negative control sample. Moreover, the 
analysis showed 53BP1 protein as the major interactor of SDOS, 
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according to recent works by other groups86,88 and the ribosomal 
protein S28 as a protein-partner common to TRAP1 and SDOS, 
suggesting that both associate with ribosomes. 
 
 
 
Table 1 Complete list of SDOS and TRAP1 protein-partners identified by mass 
spectrometry analysis. Gene name, t-test value (-log10) and Gene ID were reported 
for each protein-partner. Relevant protein-partners were highlighted in color. 
TRAP1 and NUDT16L1 (red) were found in each-other list. RPS28 (blue) was 
found in both lists. 
 
To confirm TRAP1/SDOS interaction in HeLa cells, we performed 
immunoprecipitation (IP) of a myc-tagged SDOS upon transfection in 
both HeLa FITR sh-eGFP and sh-TRAP1 cells. TRAP1 silencing was 
induced for 48 hrs followed by 24 hrs of SDOS-myc transfection. 
HeLa sh-TRAP1 cells were used as negative control and the IPs were 
analysed by western blot. As shown in Fig. 1C SDOS-myc was 
Gene name t-test SDOS-eGFP/eGFP (-log10) Gene ID Gene name t-test TRAP1-eGFP/eGFP (-log10) Gene ID
NUDT16L1 12,0802 Q9BRJ7 ABCF2 14,2995 Q9UG63
TP53BP1 11,0722 Q12888 TRAP1 12,6434 Q12931
LGALS3BP 9,86244 Q08380 TOMM40 11,2559 O96008
TUBB8 9,00189 Q3ZCM7 ACAT1 8,15674 P24752
NUDT16 8,05465 Q9BRJ7 HSP90AB1 6,42103 P08238
SQSTM1 7,90479 Q13501 MIF 5,29286 P14174
TUBA1A 7,84447 Q71U36 NUDT16L1 4,57307 Q9BRJ7
CCT4 7,6541 P50991 POLDIP2 3,89041 Q9Y2S7
DYNLL1 7,46163 P63167 RPS28 3,7948 P62857
USP11 7,29486 P51784
TRAP1 6,92604 Q12931
CCT8 6,83071 P50990
SLC7A5 6,46204 Q01650
HNRNPH3 6,1067 P31942
BAG2 6,02968 O95816
TCEAL1 6,00085 Q15170
CCT5 5,88357 P48643
MIF 5,75599 P14174
SLC25A10 5,34728 Q9UBX3
TUBA4A 4,91643 P68366
RPS28 4,91507 P62857
SLC16A3 4,88154 O15427
PPP6R3 4,82287 Q5H9R7
LAMA1 4,40167 P25391
POLDIP2 4,22019 Q9Y2S7
ANKRD28 4,00495 O15084
PPP6C 3,92096 O00743
SDOS-eGFP partners TRAP1-eGFP partners
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immunoprecipitated with Myc-Trap® agarose beads which utilizes 
small recombinant antibody fragments covalently coupled to the 
surface of agarose beads recognizing the Myc-tag sequence 
EQKLISEEDL at the N-terminus, C-terminus, or internal site of the 
fusion protein. Immunoblot with anti-TRAP1 antibody revealed a 
TRAP1-immunoreactive band in the SDOS-myc IP from the sh-eGFP 
cells, whereas no bands was detected in the sh-TRAP1 negative 
control, where the lack of TRAP1 caused a loss in the co-
immunoprecipitated TRAP1 protein.  
 
 
 
 
 
Figure 1 TRAP1 and SDOS are interacting partners. (A) Total HCT116 lysate 
was immunoprecipitated using α-TRAP1 antibody following 24 hrs of SDOS-myc 
transfection and immunoblotted using the indicated antibodies. No Ab, total cellular 
extracts incubated with A/G plus agarose beads with normal mouse IgG. (B) 
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Representative image of proximity ligation assay showing the interaction of SDOS 
with TRAP1 in HCT116 cells. Positive signals of interaction are shown as red dots, 
nuclei are stained with DAPI (blue). (C) HeLa sh-eGFP and sh-TRAP1 cells were 
induced for 48 hrs. Total lysates were immunoprecipitated with Myc_trap agarose 
beads following 24 hrs of SDOS-myc transfection and immunoblotted with 
indicated antibodies.  
 
4.2. SDOS localizes in the cytosol and the ER, where it interacts 
with TRAP1 
At the beginning of my PhD, SDOS was essentially a poorly 
characterized protein identified in the cytosol where it interacts with 
Syndecan4 and Paxillin85. Only recently it has been demonstrated that 
it is involved in a specific mechanism of DNA repair with 53BP1 in 
the cell nucleus86. Therefore, I decided to further investigate its 
localization within our cellular model through a sub-cellular 
fractionation of both HeLa WT and HeLa SDOS-eGFP cells. WB 
analysis of sub-cellular compartments confirmed the cytosolic 
localization of both SDOS-eGFP and the endogenous SDOS, but more 
importantly demonstrated that SDOS localizes on the ER. TRAP1 
mitochondrial and reticular localization were also confirmed (Fig. 2A-
B). Moreover, WB analysis performed on the nuclear fraction from 
HeLa SDOS-Flag-HA cells extracts, showed that SDOS localizes in 
the nucleus as well (Fig. 2C).  
The evidence that both TRAP1 and SDOS localize in the ER 
prompted us to hypothesize that these proteins might interact in this 
specific cellular compartment. Therefore, we performed a TRAP1 IP 
from the ER fraction of both sh-eGFP and sh-TRAP1 HeLa cells, 
following 96 hrs of induction. Western blot analysis with SDOS 
antibody demonstrated that SDOS localizes on the ER as well - as 
indicated by the bands identified in the ER fraction - and that 
TRAP1/SDOS interaction occurs in this compartment, since a specific 
band immunoreactive to anti-SDOS antibodies was detected in the IP 
from the sh-eGFP cells but not in the sh-TRAP1 cells, used as a 
negative control (Fig. 2D). 
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Figure 2 SDOS interacts with TRAP1 on the ER and localizes in both the 
cytoplasm and the nucleus. (A) and (B) Total HeLa SDOS-eGFP and HeLa WT 
lysates were fractionated into mitochondrial (MITO), cytosolic (Cyto) and 
microsomal (ER) fractions as described in Materials and Methods, separated by 
SDS-PAGE and immunoblotted with α-SDOS and α-TRAP1 antibodies. The purity 
of the fractions was assessed by using α-GAPDH, α-BiP, α-VDAC1 antibodies, 
specific for each subcellular compartment. (C) Total HeLa SDOS-Flag-HA lysate 
was fractionated into cytosolic and nuclear fractions as described in Materials and 
Methods and immunoblotted with α-SDOS antibody. α-PARP and α-GAPDH 
antibodies were used to assess purity of the fractions. (D) TRAP1 and SDOS co-IP 
analysis on the microsomal fraction (ER), obtained as described in Materials and 
Methods. WB of immunoprecipitates was performed by using the indicated 
antibodies.  
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4.3. SDOS associates with actively translating polyribosomes in 
cancer cell 
Previous studies from our group demonstrated that TRAP1 role in 
protein synthesis is linked to its association with the translational 
apparatus, including ribosomes74. Starting from this observation and 
from the evidence that among the protein partners identified by mass 
spectrometry the ribosomal protein S28 was found as common to both 
TRAP1 and SDOS (Table 1), we hypothesize that SDOS might 
associates with ribosomes as previously demonstrated for TRAP1. 
Therefore, we isolated ribosomal fraction from HCT116 cell extracts 
through ultracentrifugation on a sucrose cushion. Interestingly, WB 
analysis of the fractions demonstrated that SDOS associates with 
ribosomes, as previously demonstrated for TRAP1 (Fig. 3A). The 
same result was confirmed upon expression of SDOS-myc in HCT116 
cells (Fig. 3A). 
To verify if SDOS association with ribosomes might indicate an 
influence on protein synthesis, we performed a polysome profiling 
analysis, in collaboration with Dr. Elias Bechara at CRG in Barcelona, 
by ultracentrifugation on sucrose gradients of total extracts of cells 
expressing our eGFP-fusion proteins. SDOS-eGFP and unfused eGFP 
proteins expression were induced for 24 hrs and cells were treated 
with cycloheximide (CHX) before lysis to stabilize ribosomes on 
mRNAs. The analysis of polysome profiles upon SDOS 
overexpression showed a slight reduction in the amount of active 
polyribosomes compared to the eGFP-expressing control cells, as 
shown in Figure 3B.  
Moreover, monosome and polysome fractions were collected from the 
gradient and analysed by western blot. Results demonstrated for the 
first time that SDOS associates with active polyribosomes, supporting 
the hypothesis of a role for this protein in mRNA translation (Fig. 3C). 
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Figure 3 SDOS associates with and decreases active polyribosomes. (A) 
Ribosomal purification from HCT116 cells and HCT116 cells transfected with 
SDOS-myc, followed by immunoblot with α-SDOS on Ribosomal (ribo), non-
ribosomal (non-ribo) and total lysate fractions. The purity of the fractions was 
assessed by using α-RPL3, α-βActin and α-βF1ATPase antibodies. (B) Separation of 
cytoplasmic extracts from eGFP and SDOS-eGFP cells was performed by 
ultracentrifugation on sucrose gradients as described in Materials and Methods. The 
absorbance profile, measured at 254 nm, indicates the sedimentation of the particles: 
fractions 1 and 2 free cytosolic proteins or light complexes; fractions from 3 to 5 
ribosomal subunits (60S, 40S) and monomer (80S); fractions from 6 to 12 
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polysomes. (C) Proteins from the fractions were analysed by western blot with the 
indicated antibodies. 
 
4.4. SDOS influence global protein synthesis and takes part to 
stress granules 
To confirm that SDOS might influence mRNA translation, we decided 
to monitor protein synthesis by radioactive labelling of newly 
synthetized proteins followed by autoradiography, either upon 
overexpression or silencing of SDOS in HeLa cells, and upon 
silencing by SDOS-directed siRNA in HCT116 cells. As shown in 
Fig. 5A, results confirmed the analysis of polysome profiling showing 
that SDOS-eGFP cells incorporate less radioactive amino acids than 
the eGFP control. Accordingly, SDOS silenced cells incorporate more 
radioactively-labelled amino acids than the relative control and this 
phenotype is observed in HCT116 cells as well, following SDOS 
transient silencing by a specific siRNA. Densitomery-based 
quantification and statistical significance of this analysis is reported in 
the right panel of Fig. 5A. Taken together, these data demonstrated 
that SDOS is able per se to influence global protein synthesis. 
Starting from the evidence that among the SDOS protein partners 
identified by MS there are components of stress granules (SGs) like 
CCT4, CCT5 and CCT889, we wondered if SDOS might take part to 
these mRNP aggregates, being involved in the well-known cross-talk 
between mRNA translation and degradation90. To test this hypothesis, 
we performed immunofluorescence (IF) analysis on HeLa SDOS-
Flag-HA cells, upon sodium arsenite (NaAsO2) treatment, a well-
known inducer of SGs, using polyA binding protein 1 (PABP1) 
antibody as a SG marker. As shown in Fig. 5B, NaAsO2 treatment 
induced formation of PABP1-containing aggregates which co-
localized with SDOS. HeLa SDOS-Flag-HA untreated cells were used 
as negative control. To further characterize the role of SDOS in these 
subcellular compartment, we performed RNA fluorescence in situ 
hybridization (FISH) analysis using fluorescently-labelled oligo (dT) 
as probe against mRNA polyA-tails following NaAsO2 treatment. 
Results showed co-localization of polyadenilated RNA with SDOS-
eGFP (Fig. 5C), thus supporting the RNA-binding capacity of SDOS. 
eGFP unfused control cells were used as negative control showing no 
co-localization. These IF analyses also confirmed SDOS nuclear 
localization as above demonstrated by cell fractionation and WB.  
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Taken together, these results suggest that SDOS might regulate 
mRNAs sorting and processing, for either re-initiation of translation or 
degradation, by taking part of SGs. 
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Figure 5 SDOS affects mRNA translation by taking part of SGs. HeLa eGFP and 
SDOS-eGFP were induced for 24 hrs; HeLa sh-GFP and sh-SDOS cells were 
induced for 48 hrs, while HCT116 cells were transfected with control or SDOS-
directed siRNA for 48 hrs. (A) Cells were incubated in cysteine/methionine-free 
medium containing 50 µCi/ml 35S-labeled cysteine/methionine for 30 min and 
washed with PBS. Lysates were collected, subjected to SDS-PAGE and analyzed by 
autoradiography. α-βActin was used to normalize the results. Immunoblot with α-
SDOS and α-eGFP antibodies was performed to verify SDOS silencing and SDOS-
eGFP overexpression. Densitometric band intensities was calculated for 3 replicates 
by assuming protein levels of the control equal 1. Numbers above bars indicate the 
statistical significance (P-value), based on one-sample t-test. (B) 
Immunofluorescence analysis showing co-localization of PABP1 (red) with SDOS-
Flag-HA (green) upon NaAsO2-mediated SG induction. (C) HeLa eGFP and SDOS-
eGFP were induced for 16 hrs and subjected to RNA-FISH analysis, which shows 
co-localization of RNA (red), stained by using fluorescently-labelled oligo (dT) as 
probes, with SDOS-eGFP (green). 
 
4.5. SDOS and TRAP1 have RNA-binding capacity 
TRAP1 role in translation was deeply investigated in our studies, 
however, as previously stated, mechanisms of substrates recognition 
are still unknown. Starting from the observation that molecular 
chaperones can have RNA-binding properties91 and that RBPs are 
involved in mRNA localization and translation49, our hypothesis is 
that TRAP1 might recognize its substrates as mRNAs, through a 
direct binding or through its interaction with putative RBP-interacting 
partners such as SDOS. 
Therefore, we combined a dual approach to demonstrate that TRAP1 
and/or SDOS are RNA-binding proteins. First, we performed a 
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polynucleotide kinase (PNK) assay and then a eGFP-based RNA-
binding assay. As for the PNK assay, HeLa FITR expressing the 
eGFP-fusion proteins, were induced and directly irradiated with UV 
light, which forms covalent bonds between protein and RNA that are 
in direct contact. Protein-RNA complexes were immunoprecipitated 
with GFP-Trap® agarose beads and treated with different 
concentration of RNaseI. At low concentration of RNase, the protein-
RNA complexes appear as a smear because of the high molecular 
weight generated by long stretches of RNAs causing a shift on the 
electrophoretic mobility of the protein. Increasing concentrations of 
RNase allow only short fragments to remain bound to the protein thus 
allowing, following T4 polynucleotide kinase catalysis and 
autoradiography, the identification of a single band corresponding to 
the target protein bound to the 32P-labeled RNAs fragments. WB 
analysis with anti-eGFP antibody performed on the same membrane 
then allows to verify that the identified band belongs to the proteins of 
interest. Our results demonstrated, for the first time, that both TRAP1 
and SDOS are novel RNA-binding proteins (Fig. 6A). In this 
experiment MOV10-YFP and unfused eGFP expressing cells were 
used as positive and negative control, respectively.  
To further demonstrate that the presence of the eGFP-fusion protein 
does not influence the RNA-binding properties, this assay was 
replicated with the Flag-HA-tagged proteins, obtaining the same 
results (Fig. 6B).  
Then, we approached this aspect in a reverse prospective, by 
performing a small-scale interactome capture. In brief, eGFP-fusion 
proteins expressing HeLa cells were directly irradiated with UV light 
and the RNA bound to the proteins was captured with oligo-dT beads. 
Following stringent washes, green fluorescence in eluates was 
measured to quantify RNA-binding. As shown in Fig. 6C, results 
confirmed the RNA-binding capacity of both TRAP1 and SDOS - 
according to what seen in the PNK assay. In this case, hnRNPC, a 
known RBP, has been used as positive control. Unfused eGFP 
expressing cells, whose eluates measurement gave no signal, were 
used as negative control. 
The use of these complementary approaches strongly demonstrated 
that TRAP1 and SDOS are novel, non-canonical, RBPs.  
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Figure 6 TRAP1 and SDOS are novel, non-canonical, RNA-binding proteins. 
(A) and (B) HeLa FITR cells were induced for 16 hrs to induce the expression of the 
fusion proteins and directly irradiated with UV light, which forms covalent bonds 
between protein and RNA that are in direct contact. Protein-RNA complexes were 
immunoprecipitated either with GFP_trap agarose beads or M2-FLAG magnetic 
agarose beads and treated with different concentration of RNaseI. Following 32P 
labelling of RNA with T4 polynucleotide kinase catalysis, the IPs were subjected to 
SDS-PAGE and autoradiography in order to visualize the target protein-labeled 
RNA complexes. Immunoblot with α-eGFP or α-FLAG antibodies were performed 
to confirm that the revealed band correspond to the protein of interest. (C) HeLa 
FITR cells were induced for different time points to induce the expression of the 
fusion proteins and with 100 μM 4-thiouridine overnight to promote PAR-CL. 
Following in vivo UV crosslinking, oligo(dT) capture, and stringent washes, green 
fluorescence in eluates and inputs was measured to quantify TRAP1-eGFP and 
SDOS-eGFP RNA binding. Unfused eGFP was used as negative control and the 
well-established RNA-binding protein hnRNPC-eGFP as a positive control for RNA 
binding. 
 
4.6. Identification of SDOS and TRAP1 directly regulated 
targets at translational level by eCLIP-inspired iCLIP and 
Ribosome Profiling 
Starting from the evidence that RBPs play fundamental roles in 
mRNA translation, we hypothesized that TRAP1 and SDOS RNA-
binding properties might be important for their role in this process. 
Therefore, we decided to perform three high throughput analyses - 
individual nucleotide resolution cross-linking and 
immunoprecipitation-sequencing (iCLIP-seq), Ribosome Profiling-
sequencing (RP-seq) and Differential Gene expression analysis (GE) - 
to identify those targets that are 1) directly bound at RNA level by 
TRAP1 and/or SDOS and 2) regulated at translational level. 
 
4.6.1. eCLIP-inspired iCLIP-seq 
To identify RNAs that are SDOS and TRAP1 direct targets, we 
performed a slightly modified version of the iCLIP-seq protocol from 
the eGFP-fusion proteins expressing HeLa cells. After UV in vivo 
cross-linking, SDOS-eGFP, TRAP1-eGFP and unfused (control) 
eGFP proteins were immunoprecipitated with GFP_trap agarose beads 
and subjected to SDS-PAGE to isolate protein-RNA complexes. 
Standard iCLIP protocol relies on the radioactive labelling of the 
protein-bound RNA in order to visualize it by autoradiography and 
avoid non-specific products to be isolated92. We omitted this step as 
previously described in the eCLIP protocol93 and isolated the RBP-
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RNA complexes on the basis of the predicted RBP-IP molecular 
weight observed by WB. The RNA was then isolated, reverse 
transcribed and sequenced by Next-Generation sequencing. We 
performed three independent iCLIP analyses that show poor 
correlation due to the variability of the experiment. Therefore, we 
decided to analyse all the libraries and to consider positive all the 
targets showing a False Discovery Rate (FDR) <0.05 and specificity 
for the target protein (no peaks detected in the eGFP negative control). 
This cut-off reveals a set of 4453 targets for SDOS-eGFP and 687 
targets for TRAP1-eGFP respectively. 
Interestingly, a gene ontology (GO) analysis performed on these lists 
showed that some of the top biological pathways enriched in the 
iCLIP data are common to both TRAP1 and SDOS. Among them, 
metabolic pathways, PI3K-Akt signaling pathway, focal adhesion, 
proteoglycans in cancer, endocytosis (Fig. 7A). This is of particular 
interest for the hypothesis that SDOS and TRAP1 might share 
functional roles, based on the relevant evidence that TRAP1 and 
SDOS are among the top protein partners of one another. On one 
hand, we demonstrated that TRAP1 is responsible for a metabolic 
rewiring in ovarian cancer cells which, in turn, is responsible for the 
inflammation-induced platinum resistance69. Moreover, our previous 
works demonstrated that TRAP1 affects cell migration through a 
regulation of the PI3K-Akt axis76. On the other hand, it was 
demonstrated that SDOS is involved in the assembly of focal 
adhesions through its interaction with Paxillin and Syndecan-485. 
Therefore, it will be interesting to verify if SDOS and TRAP1 might 
work together in one (or both) of these shared pathways in the near 
future. Besides, analysis for disease-associated genes of SDOS iCLIP 
data showed enrichment of genes mostly responsible for neurological 
disorder, which can be caused by aberrant accumulation of SGs100, 
thus supporting our evidence about a role for SDOS in these 
subcellular compartments, and ciliopathies, which are commonly 
caused by defect in the primary cilia94 (Fig. 7B). Among them, Joubert 
Syndrome (JBS), whose associated-genes were also enriched in 
TRAP1 iCLIP data. Furthermore, analysis for disease-associated 
genes of TRAP1-iCLIP showed enrichment of genes involved in 
several types of cancer. Among the others, colorectal and ovarian 
cancer, which are consistent with the well-characterized role of 
TRAP1 in these cancer types65,69 (Fig. 7B).  
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Figure 7 SDOS and TRAP1 iCLIP targets share common biological pathways. 
(A) and (B) Analyses of biological pathways and diseases-associated genes from 
SDOS and TRAP1 iCLIP data using Advaita Bio’s iPathwayGuide. 
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4.6.2.  Ribosome Profiling-seq and Gene expression  
In order to identify those targets regulated by SDOS and/or TRAP1 at 
translational level, we performed Ribosome Profiling (RP)-sequencing 
from our eGFP-fusion proteins expressing HeLa cells. This technique 
allows to obtain quantitative information about translation by deep 
sequencing of ribosome-protected fragments (RPFs) upon CHX 
treatment, which stabilizes ribosomes on the mRNAs, that correspond 
to the actively translated mRNAs 95. In brief, RNA was extracted from 
isolated ribosome and RPFs were selected, by cutting the 
corresponding gel bands between 28 and 32 nucleotides of size. Then, 
rRNAs were removed, the RNA circularized and sequenced. To 
exclude a transcriptional regulation of the identified RP targets we 
performed a GE analysis from the same cell lines. Three independent 
experiments were performed for both approaches to look for 
statistically significant genes. As for the RP, we decided to conduct 
our subsequent analyses by taking in consideration those targets 
showing a Fold Change > 3.0. This cutoff allowed us to identify 1974 
differentially regulated RPFs in SDOS-eGFP and and 1779 in 
TRAP1-eGFP cells respectively. Besides, the GE analysis showed 78 
and 738 differentially expressed genes (DEGs) upon SDOS-eGFP and 
TRAP1-eGFP overexpression. Then, we normalized the RPFs by 
ruling out the genes also present in the differential GE analysis, in 
order to select only those targets regulated at translational level. 
SDOS-targets normalization let us to identify 13 genes regulated both 
at transcriptional and translational level (Fig. 8A). As for TRAP1, the 
overlap between the RP and the GE lists showed that 97 genes are 
regulated at both level (Fig. 8A). Interestingly 209 RPFs resulted 
upregulated in both SDOS and TRAP1 RP libraries and, similarly, 254 
were downregulated in both (Fig. 8B).  
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Figure 8 SDOS and TRAP1 are mostly involved in a translational regulation of 
specific substrates. (A) Venn diagrams showing SDOS-eGFP and TRAP1-eGFP 
RP and GE data in order to normalize differentially expressed RPFs. (B) Diagrams 
showing the overlapping of SDOS-eGFP and TRAP1-eGFP RP data. 
 
4.6.3. Differentially expressed genes analysis 
To look for selective pathways perturbated at gene expression level by 
SDOS and TRAP1, we performed a GO analysis on the above-
mentioned GE data. Analysis for DEGs upon SDOS-eGFP 
overexpression showed, among the top downregulated biological 
pathways, enrichment in genes involved in cytoplasmic translation, 
translational termination, large ribosomal subunit, structural 
constituent of ribosomes and mitochondrial translation, strongly 
supporting our data about the influence of SDOS in mRNA translation 
(Fig. 9A). Considering that preliminary data from our group 
demonstrated that TRAP1 influence not only cytoplasmic translation - 
as already described - but also mitochondrial translation, it will be 
interesting to verify if SDOS might play a role in this process together 
with TRAP1 or if it might be fundamental for TRAP1-dependent 
mitochondrial translation regulation. Moreover, among the top 
downregulated pathways we also found enrichment in NADH 
dehydrogenase activity and amide biosynthetic process-associated 
genes (Fig. 9A), in agreement with the metabolic pathways-enriched 
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genes identified by iCLIP analysis, supporting a role for SDOS in the 
regulation of cell metabolism that could be orchestrated together with 
TRAP1. Analysis of the top upregulated biological pathways showed, 
among the others, enrichment in genes involved in nucleus 
localization, according to SDOS nuclear localization and its role in 
53BP1-dependent repair pathway86, and centrosome cycle (Fig. 9A). 
Centrosome is linked to cilia, since they represent distinct functional 
states of the same organelle, thus supporting the evidence that SDOS-
bound transcripts are associated with ciliopathies. As for TRAP1, GO 
analysis of DEGs showed enrichment in genes associated to 
respiratory chain, oxidative phosphorylation, mitochondrial electron 
transport chain and cellular respiration among the top downregulated 
biological pathways (Fig. 9B). This evidence strongly supported our 
data about a TRAP1-dependent metabolic rewiring in ovarian cancer69 
and, more in general, its role in the regulation of cell metabolism, 
even if it remains to elucidate whether this regulation has an 
oncogenic or oncosuppressive potential79. Besides, among the top 
upregulated biological pathways, we found enrichment in genes 
involved in ribosomal assembly and intrinsic apoptotic signaling 
pathway in response to endoplasmic reticulum stress response (Fig. 
9B). Accordingly, we previously demonstrated that TRAP1 regulation 
of protein synthesis allows the synthesis of selective stress responsive 
proteins, such as ATF4 and Bip, thus providing protection against ER 
stress74. 
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Figure 9 SDOS and TRAP1 gene expression data analysis confirm their 
functional role. (A) and (B) Analyses of biological pathways from SDOS-eGFP and 
TRAP1-eGFP GE data through GSEA. DEGs with p-values <0.05 were retained.  
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4.7. SDOS directly binds and regulates translation of transcripts 
of genes involved in primary cilia formation  
iCLIP, RP and GE analyses produced a very high amount of data. 
Therefore, it was necessary to intersect the distinct results to have a 
global picture and to be able to select the most interesting regulated 
pathways associated to the proteins of interest. In this context, we 
decided to focus our downstream analyses on SDOS at first, since, as 
mentioned above, its functions are largely unknown. SDOS-eGFP 
iCLIP and RP data intersection identified a subset of 386 common 
genes. Analysis of diseases-associated genes showed, among the 
others, Joubert syndrome and Meckel Gruber syndrome, both 
belonging to ciliopathies family (Fig. 10A). In particular, TMEM67, 
CC2D2A and KIF7 were reported as genes associated to these 
diseases (Fig. 10B). Accordingly, cellular component-associated 
genes to the given subset showed enrichment in cilium-associated 
genes (Fig. 10C). Among the others, the above mentioned CC2D2A, 
TMEM67, KIF7 plus TMEM107 and TOPORS, all of them also 
known to cause ciliopathies94. Taken together, these analyses were 
promising, since a new area of research is recently emerging linking 
cilia and centrosome proteins to DNA-damage response (DDR)96, a 
process for which only recently it was described a role for SDOS86.  
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Figure 10 SDOS-directly regulated targets are involved in ciliopathies. (A) 
Venn diagram showing the number of SDOS-eGFP targets identified by iCLIP and 
RP. (B) and (C) Diseases-associated and cellular component-associated genes 
identified by using Advaita Bio’s iPathwayGuide. 
 
Starting from this evidence, among the iCLIP and RP common subset, 
we decided to validate those genes involved in cilia formation that 
were previously associated to ciliopathies: AHI1, CC2D2A, KIF7, 
NPHP1, RPGRIP1L, TCTN1, TMEM67, TMEM107, TOPORS, 
TTC21B and ZNF423. To confirm that these targets were bound at 
RNA level by SDOS as suggested by iCLIP-seq, we performed IPs of 
SDOS-eGFP and unfused eGFP followed by RNA extraction and 
qPCR, to measure the enrichment of targets mRNA in SDOS-eGFP 
compared to the eGFP negative control. In particular, among the 
selected group of genes, we focused on transcripts found at least in 2 
out of 3 iCLIP libraries. Results confirmed that, among the others, 
TMEM107, CC2D2A and KIF7 mRNAs were significantly enriched 
in the SDOS-eGFP IP, while no enrichment was observed for ACTIN 
mRNA used as negative control (Fig. 11A). In order to confirm that 
all these genes were not differentially expressed upon SDOS 
overexpression, as suggested by GE data, we performed a qPCR 
analysis from SDOS-eGFP and unfused eGFP HeLa expressing cells. 
Results showed no changes at transcriptional level following SDOS-
eGFP overexpression for all the selected genes but KIF7 (Fig 11B). 
Finally, we have begun to validate by WB the translation regulation of 
those targets present in the RP-seq data, either upon SDOS-eGFP 
overexpression or SDOS silencing. As shown in Fig. 11C, WB 
analysis of TMEM107 confirmed its down-regulation upon SDOS-
eGFP overexpression, consistently with RP-seq. Accordingly, SDOS 
silencing caused an increase in TMEM107 protein level.  
 
Results 
 
58 
 
 
 
Figure 11 SDOS is an RBP which binds mRNA of genes involved in primary 
cilia formation and regulates their translation. (A) Validation of iCLIP results by 
RT-PCR of 3 biological replicates in RNA-immunoprecipitation experiments 
following both SDOS-eGFP or eGFP IP and RNA extraction. RNA enrichment in 
SDOS-eGFP IP relative to the eGFP control of specific substrates was normalized to 
a spike-in control (dashed line). ACTIN was used as negative control showing no 
enrichment. (B) RT-PCR of a subset of 11 genes responsible for ciliopathies from 
HeLa SDOS-eGFP and eGFP cells upon 24 hrs of induction. Data are expressed as 
mean± S.E.M. from four independent experiments with technical triplicate each. 
Numbers above bars indicate the statistical significance (P-value), based on one-
sample t-test. Red line indicates expression level of the relative control. (C) WB 
analysis following SDOS overexpression or silencing with the indicated antibodies. 
Numbers indicate densitometric band intensities, calculated by assuming protein 
levels of the control equal 1. 
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5. DISCUSSION 
Post-transcriptional events represent a complex and intricate layer of 
gene expression regulation. Accordingly, many players are required to 
fine tune these processes, allowing cells to adapt to internal or external 
stimuli when needed. Among the others, RBPs are emerging as key 
players in the regulation of each step of RNA life, from splicing and 
polyadenylation to transport, localization, translation and 
degradation11. Given their fundamental role in these processes, the 
interest in RBPs has grown over the years with hundreds of novel 
RBPs recently identified that lack the classical RBDs identified so far, 
therefore known as “non-canonical” RBPs4. Considering that cancer 
cells strongly rely on post-transcriptional mechanisms for the re-
programming of gene expression to be able to survive in critical 
conditions, it is not surprising that perturbations of RBP-associated 
networks can contribute to cancer development in several ways52. 
RBPs dysregulation in cancer arise from various mechanisms, 
including genomic alterations, transcriptional and post-transcriptional 
control, and post-translational modifications (PTMs). In particular, 
PTMs are the main responsible of RBPs dysfunction, with RNA-
recognition elements susceptible to various PTMs thus influencing 
RBPs binding properties, function or localization52. Among the post-
transcriptional mechanisms governed by RBPs intervention, 
translation is one of the most commonly dysregulated in cancer. 
Several studies demonstrated that all of the major oncogenic signaling 
pathways associated with cancer - PI3K/AKT/mTOR, RAS/MAPK, 
and Wnt/b-catenin – lead to dysregulation of translation47. In this 
context, we investigated the role of two putative RBPs: the molecular 
chaperone TRAP1 and its putative partner SDOS. 
TRAP1 was extensively described for its role in cancer through its 
anti-apoptotic and anti-oxidant functions associated with its 
mitochondrial localization97,98. Very recently, a growing interest is 
emerging about the role of TRAP1 in the regulation of cancer cell 
metabolism that we demonstrated to be responsible for resistance to 
antitumoral drugs in ovarian cancer69. However, our previous works 
helped to describe a more complex scenario, due to a newly identified 
localization of TRAP1 on the endoplasmic reticulum, linked to a 
specific function. Indeed, we demonstrated that TRAP1 is responsible 
for a co-translational regulation of specific substrates mostly directed 
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to mitochondria72. Moreover, TRAP1 associates with the translational 
apparatus, including both ribosomes and translational factors, thus 
influencing translation and affecting related features such as cell 
migration74,76. In this context, the aim of this work is to shed further 
light about previously suggested RNA-binding properties of TRAP183 
and its interacting-partner SDOS. SDOS was only recently described 
to have a role in cancer, by masking the histone methyl-lysine binding 
function of 53BP1 - with whom it forms a stable complex - thus 
influencing double-strand break repair86. Our data strongly 
demonstrated that SDOS is a novel TRAP1-interacting partner and 
that this interaction occurs on the ER, supporting the hypothesis of a 
cooperation between SDOS and TRAP1 in translation. Accordingly, 
this work demonstrated that SDOS associates with ribosomes as well. 
Association with ribosomes often reflects an influence on the rate of 
translation which ensures correct translation and co-translational 
folding of newly synthetized proteins99. Such regulation is relevant in 
cancer since dysregulated biosynthesis is one of the hallmark of 
cancer cells; moreover substrate-specific regulations can take place to 
enhance translation of proteins involved in carcinogenesis100. 
Polysome profiling following SDOS overexpression showed changes 
in the amount active polysomes relative to the control. This data was 
confirmed by monitoring of global protein synthesis through 
radioactive labelling of newly synthetized proteins which 
demonstrated that SDOS influence global protein synthesis. 
Moreover, SDOS is a paralog of NUDT16 proteins which are 
decapping enzymes, therefore involved in the formation of mRNPs 
aggregates to drive mRNAs degradation. Although SDOS lacks the 
decapping activity84, component of SGs have been identified in this 
work by MS as putative SDOS partners, namely CCT4, CCT5 and 
CCT889. Therefore, we hypothesize that SDOS, differently from 
NUDT16, might take part to these mRNPs granules that are not 
anymore considered as site for mRNAs degradation but rather storage 
site for mRNAs sorting and processing, for either re-initiation of 
translation or degradation90. Aberrant SGs formation contributes to 
neurodegenerative disease and some cancers101. Interestingly, we 
identified SDOS as a new component of SGs, where it co-localizes 
with polyadenylated RNAs upon sodium arsenite treatment, a well-
known inducer of SGs, thus supporting a role for SDOS in the 
processing and sorting of specific mRNAs.  
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The most relevant finding of this work is the demonstration that both 
TRAP1 and SDOS are able to bind RNAs, result achieved by 
combining two highly specific approaches. Given the central role 
played by RBPs in mRNA translation, we hypothesize that the RNA-
binding properties of both SDOS and TRAP1 might be relevant for 
their contribution to this process. The combination of three powerful 
high throughput techniques – iCLIP, Ribosome Profiling and 
differential Gene expression analysis – allowed us to demonstrate that 
TRAP1 and SDOS are, indeed, able to directly bind a subset of 
specific substrates at RNA level and to regulate them at translational 
level. However, SDOS-directly regulated targets did not extensively 
overlap those of TRAP1, suggesting that the two proteins have distinct 
properties although sharing some regulatory functions. 
Analysis of TRAP1 data mostly confirmed its previously described 
role in metabolism and translation, raising questions about the 
existence of a cross-talk between these two processes. Accordingly, 
among the TRAP1-directly regulated targets that we identified, there 
are several proteins involved in the regulation of cell metabolism like 
UQCC1, UQCRC2, GFPT1 and PFKM among others.  
Surprisingly, analyses of SDOS-directly regulated targets not only 
confirmed its possible role in translation but clearly indicated that 
most of these targets are responsible for ciliopathies, when mutated or 
dysregulated. In particular, Joubert Syndrome, Meckel Gruber 
syndrome and Retinitis pigmentosa are among the diseases associated 
to the gene set enriched in the SDOS target list. Ciliopathies belong to 
a class of rare diseases which are caused by defects in primary cilia94. 
Primary cilia act as key coordinators of signaling pathways during 
development and in tissue homeostasis. These organelles were found 
in the majority of cells that are in G0 phase; when cells re-enter the 
cell cycle and start to divide, primary cilia are resorbed and grown 
again once the cells become quiescent102. Studies relative to cilia and 
cancer demonstrated that usually cancer cells display a reduction in 
the number of cilia, due to mechanisms involving the loss of genes 
required for ciliogenesis rather than altered proliferation rate103. 
Accordingly, it was recently demonstrated that inhibition of 
ciliogenesis led to earlier tumor formation, faster tumor growth rate, 
higher tumor grade formation, and increased metastasis in breast 
cancer104. Association of cilia with cancer is particularly interesting to 
further dissect the role of SDOS in cancer. Indeed, a new area of 
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research is exploring the possibility of a link between cilia and DNA-
damage response96, a process in which SDOS plays a fundamental 
role as recently described86. Vertii A. et al suggested that the ATM co-
factor ATMIN is not only involved in DNA damage but also acts a 
transcriptional regulator of ciliary DYNLL1, that we found as a SDOS 
protein partner by MS. In line with this evidence, we also found FXR2 
among the transcripts bound by SDOS and upregulated among 
differentially expressed RPFs. FXR2 is an RBP - often co-deleted 
with p53 in some cancers105 – that, according to bioinformatic 
analyses, might interact with ubiquitin C, an ubiquitin ligase, which 
regulates ARL6106, a protein involved in membrane protein trafficking 
at the base of the ciliary organelle107. Therefore, among the identified 
SDOS-directly regulated targets, we validated a subset of 11 genes 
whose dysregulation was previously demonstrated to cause 
ciliopathies. None of these genes is regulated at transcriptional level 
by SDOS, except KIF7. Among them TMEM107 was of particular 
interest because the snoRNA U8, that is the main target of NUDT16-
decapping activity and whose recognition seems to be conserved by 
SDOS84, is located in the 3’-UTR region of TMEM107. Of the 
selected subset of genes, we validated CC2D2A, KIF7 and TMEM107 
as SDOS-bound transcripts, according to our iCLIP data. Moreover, 
we confirmed that, among the others, TMEM107 is regulated at 
translational level either upon SDOS overexpression or silencing. 
These data strongly support the idea of a role for SDOS in primary 
cilia formation and related ciliopathies or cancer. One possibility 
might be that SDOS/DYNLL1 interaction regulates SDOS binding to 
cilia-associated transcripts which, in turn, could be implicated in 
mRNAs transport in the proximity of cilia and localized translation, 
and this signaling could be associated with DDR. 
Taken together, the data of this work strongly demonstrated that both 
SDOS and TRAP1 are involved in a translational regulation of 
specific substrates bound at RNA level that are involved in pathways 
often dysregulated in cancer, like metabolism and ciliogenesis among 
the others. Intriguingly, a link between cilia defects and metabolic 
dysfunction was already described in patient affected by obesity and 
type II diabetes108, suggesting the existence of a possible cross-talk 
between these processes in cancer.  
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insegnato a non smettere mai di credere nei miei sogni, senza mai 
influenzare le mie scelte, nonostante le dinamiche di questo mondo 
talvolta risultino difficili da comprendere per chi ne è fuori e vuole 
solo il meglio per te. 
Grazie a nonno Rosario, per gli occhi che brillano quando parla di me 
e del mio lavoro. 
Grazie a tutti gli amici sempre presenti, per i continui tentativi di 
capire quello che faccio, soprattutto quando mi è capitato di dire: 
“Devo passare un attimo in lab a splittare le cellule!”. 
Fare il ricercatore può farti sentire solo il più delle volte, perché non è 
facile lasciar entrare le persone in questo mondo, riuscire a spiegare 
con parole semplici cosa significhi fare ricerca. Per non parlare del 
fatto che i fallimenti sono molto più frequenti delle vittorie nel nostro 
mondo. Eppure, quando quella piccola vittoria arriva, è in grado di 
spazzare via mesi di frustrazioni e rabbia, e riporta a galla i motivi che 
ti hanno spinto a sceglierlo, quel mestiere. Riporta alla luce la voglia 
  
 
di fare qualcosa di buono. Ed è per questo che, nonostante tutto, non 
riesco ad immaginare un lavoro più bello. 
 
